

<!-- RR Donnelley Xcelerate Instance Document, based on XBRL 2.1  http://www.edgar-online.com/ -->
<!-- Version:  6.21.0 -->
<!-- Round: 76f63931-ae09-4549-b350-78fb8e892729 -->
<!-- Creation date: 2013-08-08T15:56:39Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2013-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2013-01-31" xmlns:mnov="http://www.medicinova.com/20130630" xmlns:us-types="http://fasb.org/us-types/2013-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2012-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2013-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:utr="http://www.xbrl.org/2009/utr">
  <xbrll:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="mnov-20130630.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" />
  <us-gaap:DeferredRevenue contextRef="eol_PE402953--1310-Q0008_STD_0_20111031_0" unitRef="iso4217_USD" decimals="-5" id="id_2677847_BD5FAE21-42B4-4A69-8B8B-3F39112EEBE5_1001_0">2500000</us-gaap:DeferredRevenue>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE402953--1310-Q0008_STD_0_20111031_0_734171x796264" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2677847_9F4EDBF1-50EB-497C-9A01-EE6166B1A9AD_5001_6">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="eol_PE402953--1310-Q0008_STD_0_20111031_0_734171x796264" unitRef="pure" decimals="2" id="id_2677847_9F4EDBF1-50EB-497C-9A01-EE6166B1A9AD_5001_7">0.03</us-gaap:EquityMethodInvestmentOwnershipPercentage>
  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="eol_PE402953--1310-Q0008_STD_0_20111031_0_734171x796264" unitRef="shares" decimals="INF" id="id_2677847_9F4EDBF1-50EB-497C-9A01-EE6166B1A9AD_5001_9">10</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE402953--1310-Q0008_STD_0_20111031_0_734171x796264" unitRef="iso4217_USD_per_shares" decimals="3" id="id_2677847_9F4EDBF1-50EB-497C-9A01-EE6166B1A9AD_5001_3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="eol_PE402953--1310-Q0008_STD_0_20120822_0" unitRef="shares" decimals="0" id="id_2677847_598615ED-0C0F-4316-97A2-6F2C5CA95095_1002_0">130000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="eol_PE402953--1310-Q0008_STD_0_20120822_0" unitRef="iso4217_USD_per_Warrants" decimals="2" id="id_2677847_598615ED-0C0F-4316-97A2-6F2C5CA95095_1002_1">1.88</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <mnov:ClassOfWarrantOrRightFairValue contextRef="eol_PE402953--1310-Q0008_STD_0_20120822_0" unitRef="iso4217_USD" decimals="-5" id="id_2677847_598615ED-0C0F-4316-97A2-6F2C5CA95095_1002_4">100000</mnov:ClassOfWarrantOrRightFairValue>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="eol_PE402953--1310-Q0008_STD_0_20130509_0_734171x772521" unitRef="shares" decimals="0" id="id_2677847_054A7B11-702F-4790-A78F-38E35EAE70D6_3001_2">869047</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="eol_PE402953--1310-Q0008_STD_0_20130509_0_734171x772521" unitRef="iso4217_USD_per_Warrants" decimals="2" id="id_2677847_054A7B11-702F-4790-A78F-38E35EAE70D6_3001_3">3.15</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <dei:EntityCommonStockSharesOutstanding contextRef="eol_PE402953--1310-Q0008_STD_0_20130807_0" unitRef="shares" decimals="INF" id="id_2677847_F38A9F63-AAA3-4C4C-A1AA-B15C0E62A3E9_2_500005">22313789</dei:EntityCommonStockSharesOutstanding>
  <mnov:ConsistsOfEachFirmCommitmentUnderwrittenPublicOfferingUnit contextRef="eol_PE402953--1310-Q0008_STD_0_20110323_0" id="id_2677847_CAFC5452-4A4E-45FC-95E8-A251AC1FF285_1_2">Each unit consisting  of one share of common stock and one warrant</mnov:ConsistsOfEachFirmCommitmentUnderwrittenPublicOfferingUnit>
  <mnov:NumberOfUnitsInFirmCommitmentUnderwrittenPublicOffering contextRef="eol_PE402953--1310-Q0008_STD_0_20110323_0" unitRef="shares" decimals="0" id="id_2677847_CAFC5452-4A4E-45FC-95E8-A251AC1FF285_1_0">2750000</mnov:NumberOfUnitsInFirmCommitmentUnderwrittenPublicOffering>
  <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="eol_PE402953--1310-Q0008_STD_0_20120331_0" unitRef="pure" decimals="2" id="id_2677847_5838D125-076D-4BB8-B8AF-2891F45F2C87_1001_1">0.30</us-gaap:EquityMethodInvestmentOwnershipPercentage>
  <us-gaap:CommonStockSharesSubscriptions contextRef="eol_PE402953--1310-Q0008_STD_0_20130417_0_705999x732135_734171x806301" unitRef="iso4217_USD" decimals="-6" id="id_2677847_E4116147-5666-4500-819F-F07D0ADDBCB6_3001_0">6000000</us-gaap:CommonStockSharesSubscriptions>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="eol_PE402953--1310-Q0008_STD_0_20130529_0_797208x760742" unitRef="shares" decimals="0" id="id_2677847_AF7F1EB4-6432-4529-9748-45C079E09404_3001_1">119047</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="eol_PE402953--1310-Q0008_STD_0_20130529_0_797208x760742" unitRef="iso4217_USD_per_Warrants" decimals="2" id="id_2677847_AF7F1EB4-6432-4529-9748-45C079E09404_3001_3">3.38</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE402953--1310-Q0008_STD_0_20120630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_1002_37">7258530</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <mnov:OtherAssetAmortizationPeriod contextRef="eol_PE402953--1310-Q0008_STD_0_20120831_0" id="id_2677847_598615ED-0C0F-4316-97A2-6F2C5CA95095_1001_5">P1Y</mnov:OtherAssetAmortizationPeriod>
  <mnov:ClassOfWarrantOrRightExpirationPeriod contextRef="eol_PE402953--1310-Q0008_STD_0_20120831_0" id="id_2677847_598615ED-0C0F-4316-97A2-6F2C5CA95095_1001_3">P5Y</mnov:ClassOfWarrantOrRightExpirationPeriod>
  <mnov:StockPurchaseAgreementNumberOfSharesCanBePurchasedPerDay contextRef="eol_PE402953--1310-Q0008_STD_0_20120831_0_705999x827742_709650x713713_711502x716112" unitRef="shares" decimals="INF" id="id_2677847_9CF8DC32-C639-4465-AAAF-4A3E5A13BD94_4001_5">50000</mnov:StockPurchaseAgreementNumberOfSharesCanBePurchasedPerDay>
  <mnov:StockPurchaseAgreementValueOfSharesCanBePurchasedPerDay contextRef="eol_PE402953--1310-Q0008_STD_0_20120831_0_705999x827742_709650x713713_711502x716112" unitRef="iso4217_USD" decimals="INF" id="id_2677847_9CF8DC32-C639-4465-AAAF-4A3E5A13BD94_4001_6">500000</mnov:StockPurchaseAgreementValueOfSharesCanBePurchasedPerDay>
  <mnov:VolumeWeightedAveragePurchaseAsPercentageOfAggregateSharesOfStockTradedNextBusinessDay contextRef="eol_PE402953--1310-Q0008_STD_0_20120831_0_705999x827742_709650x713713_711502x716112_734171x796264" unitRef="pure" decimals="2" id="id_2677847_9CF8DC32-C639-4465-AAAF-4A3E5A13BD94_5001_10">0.30</mnov:VolumeWeightedAveragePurchaseAsPercentageOfAggregateSharesOfStockTradedNextBusinessDay>
  <us-gaap:CommonStockSharesSubscriptions contextRef="eol_PE402953--1310-Q0008_STD_0_20120831_0_705999x827742_709650x713713_734171x796264" unitRef="iso4217_USD" decimals="-6" id="id_2677847_9CF8DC32-C639-4465-AAAF-4A3E5A13BD94_6001_0">20000000</us-gaap:CommonStockSharesSubscriptions>
  <mnov:VolumeWeightedAveragePurchaseAsPercentageOfNextBusinessDayNasdaqVolumeWeightedAveragePrice contextRef="eol_PE402953--1310-Q0008_STD_0_20120831_0_705999x827742_709650x713713_734171x796264" unitRef="pure" decimals="2" id="id_2677847_9CF8DC32-C639-4465-AAAF-4A3E5A13BD94_6001_11">0.95</mnov:VolumeWeightedAveragePurchaseAsPercentageOfNextBusinessDayNasdaqVolumeWeightedAveragePrice>
  <mnov:VolumeWeightedAveragePurchaseAsPercentageOfAggregateSharesOfStockTradedNextBusinessDay contextRef="eol_PE402953--1310-Q0008_STD_0_20120831_0_705999x827742_709650x713713_734171x796264" unitRef="pure" decimals="2" id="id_2677847_9CF8DC32-C639-4465-AAAF-4A3E5A13BD94_6001_9">0.15</mnov:VolumeWeightedAveragePurchaseAsPercentageOfAggregateSharesOfStockTradedNextBusinessDay>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE402953--1310-Q0008_STD_0_20130630_0" unitRef="shares" decimals="INF" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_1_29">22148493</us-gaap:CommonStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE402953--1310-Q0008_STD_0_20130630_0" unitRef="shares" decimals="INF" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_1_25">220000</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="eol_PE402953--1310-Q0008_STD_0_20130630_0" unitRef="shares" decimals="INF" id="id_2677847_E23DA0B0-021D-48D2-B4F7-69A00A6528BF_1001_400006">2109379</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE402953--1310-Q0008_STD_0_20130630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2677847_69759BC3-912F-4D68-B851-7DE8E80772BD_1001_5">5.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE402953--1310-Q0008_STD_0_20130630_0" unitRef="shares" decimals="INF" id="id_2677847_E23DA0B0-021D-48D2-B4F7-69A00A6528BF_1001_400005">3329794</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE402953--1310-Q0008_STD_0_20130630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_1_22">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE402953--1310-Q0008_STD_0_20130630_0" unitRef="shares" decimals="INF" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_1_24">220000</us-gaap:PreferredStockSharesIssued>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="eol_PE402953--1310-Q0008_STD_0_20130630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2677847_69759BC3-912F-4D68-B851-7DE8E80772BD_1001_6">6.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE402953--1310-Q0008_STD_0_20130630_0" unitRef="shares" decimals="INF" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_1_28">100000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:TreasuryStockShares contextRef="eol_PE402953--1310-Q0008_STD_0_20130630_0" unitRef="shares" decimals="INF" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_1_34">0</us-gaap:TreasuryStockShares>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE402953--1310-Q0008_STD_0_20130630_0" unitRef="iso4217_USD_per_shares" decimals="3" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_1_27">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE402953--1310-Q0008_STD_0_20130630_0" unitRef="shares" decimals="INF" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_1_23">3000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE402953--1310-Q0008_STD_0_20130630_0" unitRef="shares" decimals="INF" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_1_30">22148493</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE402953--1310-Q0008_STD_0_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_1_18">1694163</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE402953--1310-Q0008_STD_0_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_1_16">1075633</us-gaap:LiabilitiesCurrent>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE402953--1310-Q0008_STD_0_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_1_32">-78594</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="eol_PE402953--1310-Q0008_STD_0_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_1_14">490810</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="eol_PE402953--1310-Q0008_STD_0_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_31FA999C-1748-4726-BFD4-2F0A5CBF45DC_1_2">169372</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:AdditionalPaidInCapital contextRef="eol_PE402953--1310-Q0008_STD_0_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_1_31">325568447</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE402953--1310-Q0008_STD_0_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_1_12">130817</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="eol_PE402953--1310-Q0008_STD_0_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_31FA999C-1748-4726-BFD4-2F0A5CBF45DC_1_1">161920</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:StockholdersEquity contextRef="eol_PE402953--1310-Q0008_STD_0_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_1_36">22950973</us-gaap:StockholdersEquity>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE402953--1310-Q0008_STD_0_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_1_35">-301438840</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:PreferredStockValue contextRef="eol_PE402953--1310-Q0008_STD_0_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_1_21">2200</us-gaap:PreferredStockValue>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="eol_PE402953--1310-Q0008_STD_0_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_1_13">454006</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:Liabilities contextRef="eol_PE402953--1310-Q0008_STD_0_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_1_19">4725796</us-gaap:Liabilities>
  <us-gaap:CommonStockValue contextRef="eol_PE402953--1310-Q0008_STD_0_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_1_26">22149</us-gaap:CommonStockValue>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE402953--1310-Q0008_STD_0_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_1_37">27676769</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="eol_PE402953--1310-Q0008_STD_0_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_1_17">1956000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
  <us-gaap:Goodwill contextRef="eol_PE402953--1310-Q0008_STD_0_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_1_5">9600241</us-gaap:Goodwill>
  <us-gaap:TreasuryStockValue contextRef="eol_PE402953--1310-Q0008_STD_0_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_1_33">1124389</us-gaap:TreasuryStockValue>
  <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures contextRef="eol_PE402953--1310-Q0008_STD_0_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_1_7">673374</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE402953--1310-Q0008_STD_0_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_1_8">105513</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:Assets contextRef="eol_PE402953--1310-Q0008_STD_0_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_1_9">27676769</us-gaap:Assets>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE402953--1310-Q0008_STD_0_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_1_2">12017480</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="eol_PE402953--1310-Q0008_STD_0_20130630_0" unitRef="iso4217_USD" decimals="INF" id="id_2677847_C8F5AFBB-8CC3-44E8-AF69-F4F03C1CD614_1_2">171000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="eol_PE402953--1310-Q0008_STD_0_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_C8F5AFBB-8CC3-44E8-AF69-F4F03C1CD614_1_0">209000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="eol_PE402953--1310-Q0008_STD_0_20130630_0" unitRef="iso4217_USD" decimals="-5" id="id_2677847_F2CBBBB1-EF2F-453A-B8CA-07DCF638AB21_4001_5">2200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:CashFDICInsuredAmount contextRef="eol_PE402953--1310-Q0008_STD_0_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_E72504D7-640A-4034-B9E0-97D140007F5F_1_0">250000</us-gaap:CashFDICInsuredAmount>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE402953--1310-Q0008_STD_0_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_1_3">480161</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:AssetsCurrent contextRef="eol_PE402953--1310-Q0008_STD_0_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_1_4">12497641</us-gaap:AssetsCurrent>
  <mnov:AccruedResearchAndDevelopmentExpenseCurrent contextRef="eol_PE402953--1310-Q0008_STD_0_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_31FA999C-1748-4726-BFD4-2F0A5CBF45DC_1_0">122714</mnov:AccruedResearchAndDevelopmentExpenseCurrent>
  <mnov:MaturityPeriodOfInvestmentInCashEquivalentsSecurities contextRef="eol_PE402953--1310-Q0008_STD_0_20130630_0" id="id_2677847_C57D7178-80F2-43E0-AE57-87CE5F9E5379_1_0">Three months  or less</mnov:MaturityPeriodOfInvestmentInCashEquivalentsSecurities>
  <mnov:InProcessResearchAndDevelopment contextRef="eol_PE402953--1310-Q0008_STD_0_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_1_6">4800000</mnov:InProcessResearchAndDevelopment>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE402953--1310-Q0008_STD_0_20130630_0_712546x711349" unitRef="iso4217_USD" decimals="-3" id="id_2677847_867C358C-1FFF-44C2-96D6-8B57D6BBD9A9_2001_1">678000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE402953--1310-Q0008_STD_0_20130630_0_712546x711349_715757x707740" unitRef="iso4217_USD" decimals="-3" id="id_2677847_867C358C-1FFF-44C2-96D6-8B57D6BBD9A9_2002_1">678000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate contextRef="eol_PE402953--1310-Q0008_STD_0_20071231_0" unitRef="pure" decimals="2" id="id_2677847_BA131555-A95F-482C-8301-BA2C44423299_1001_0">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE402953--1310-Q0008_STD_0_20111231_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_3001_36">15093124</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE402953--1310-Q0008_STD_0_20121231_0" unitRef="shares" decimals="INF" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_2_29">17407311</us-gaap:CommonStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE402953--1310-Q0008_STD_0_20121231_0" unitRef="shares" decimals="INF" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_2_25">220000</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE402953--1310-Q0008_STD_0_20121231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2677847_69759BC3-912F-4D68-B851-7DE8E80772BD_2001_1">4.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE402953--1310-Q0008_STD_0_20121231_0" unitRef="shares" decimals="INF" id="id_2677847_E23DA0B0-021D-48D2-B4F7-69A00A6528BF_2001_400001">3328981</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE402953--1310-Q0008_STD_0_20121231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_2_22">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE402953--1310-Q0008_STD_0_20121231_0" unitRef="shares" decimals="INF" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_2_24">220000</us-gaap:PreferredStockSharesIssued>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE402953--1310-Q0008_STD_0_20121231_0" unitRef="shares" decimals="INF" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_2_28">100000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:TreasuryStockShares contextRef="eol_PE402953--1310-Q0008_STD_0_20121231_0" unitRef="shares" decimals="INF" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_2_34">4186</us-gaap:TreasuryStockShares>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE402953--1310-Q0008_STD_0_20121231_0" unitRef="iso4217_USD_per_shares" decimals="3" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_2_27">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE402953--1310-Q0008_STD_0_20121231_0" unitRef="shares" decimals="INF" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_2_23">3000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE402953--1310-Q0008_STD_0_20121231_0" unitRef="shares" decimals="INF" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_2_30">17403125</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE402953--1310-Q0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_2_18">1694257</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE402953--1310-Q0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_2_16">1037792</us-gaap:LiabilitiesCurrent>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE402953--1310-Q0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_2_32">-67957</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="eol_PE402953--1310-Q0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_2_14">228124</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="eol_PE402953--1310-Q0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_31FA999C-1748-4726-BFD4-2F0A5CBF45DC_2_2">94504</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:AdditionalPaidInCapital contextRef="eol_PE402953--1310-Q0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_2_31">312293225</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE402953--1310-Q0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_2_12">491853</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="eol_PE402953--1310-Q0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_31FA999C-1748-4726-BFD4-2F0A5CBF45DC_2_1">68102</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:StockholdersEquity contextRef="eol_PE402953--1310-Q0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_2_36">14879992</us-gaap:StockholdersEquity>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE402953--1310-Q0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_2_35">-296233797</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE402953--1310-Q0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_2_15">3163</us-gaap:DeferredRevenueCurrent>
  <us-gaap:PreferredStockValue contextRef="eol_PE402953--1310-Q0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_2_21">2200</us-gaap:PreferredStockValue>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="eol_PE402953--1310-Q0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_2_13">314652</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:Liabilities contextRef="eol_PE402953--1310-Q0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_2_19">4688049</us-gaap:Liabilities>
  <us-gaap:CommonStockValue contextRef="eol_PE402953--1310-Q0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_2_26">17407</us-gaap:CommonStockValue>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE402953--1310-Q0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_2_37">19568041</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="eol_PE402953--1310-Q0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_2_17">1956000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
  <us-gaap:Goodwill contextRef="eol_PE402953--1310-Q0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_2_5">9600241</us-gaap:Goodwill>
  <us-gaap:TreasuryStockValue contextRef="eol_PE402953--1310-Q0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_2_33">1131086</us-gaap:TreasuryStockValue>
  <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures contextRef="eol_PE402953--1310-Q0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_2_7">667204</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE402953--1310-Q0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_2_8">78474</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:Assets contextRef="eol_PE402953--1310-Q0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_2_9">19568041</us-gaap:Assets>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE402953--1310-Q0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_2_2">4010530</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE402953--1310-Q0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_2_3">411592</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:AssetsCurrent contextRef="eol_PE402953--1310-Q0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_2_4">4422122</us-gaap:AssetsCurrent>
  <mnov:AccruedResearchAndDevelopmentExpenseCurrent contextRef="eol_PE402953--1310-Q0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_31FA999C-1748-4726-BFD4-2F0A5CBF45DC_2_0">152046</mnov:AccruedResearchAndDevelopmentExpenseCurrent>
  <mnov:InProcessResearchAndDevelopment contextRef="eol_PE402953--1310-Q0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_EB4EC048-DC71-45C6-A19B-2D431F0BF114_2_6">4800000</mnov:InProcessResearchAndDevelopment>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE402953--1310-Q0008_STD_0_20121231_0_712546x711349" unitRef="iso4217_USD" decimals="-3" id="id_2677847_867C358C-1FFF-44C2-96D6-8B57D6BBD9A9_1001_2">1720000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE402953--1310-Q0008_STD_0_20121231_0_712546x711349_715757x707740" unitRef="iso4217_USD" decimals="-3" id="id_2677847_867C358C-1FFF-44C2-96D6-8B57D6BBD9A9_1002_2">1720000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <dei:TradingSymbol contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" id="id_2677847_F38A9F63-AAA3-4C4C-A1AA-B15C0E62A3E9_1_400000">MNOV</dei:TradingSymbol>
  <dei:EntityRegistrantName contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" id="id_2677847_F38A9F63-AAA3-4C4C-A1AA-B15C0E62A3E9_1_400001">MEDICINOVA INC</dei:EntityRegistrantName>
  <dei:AmendmentFlag contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" id="id_2677847_18886918-561B-406D-A4CA-3FB6868936E9_1_1">false</dei:AmendmentFlag>
  <dei:EntityFilerCategory contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" id="id_2677847_F38A9F63-AAA3-4C4C-A1AA-B15C0E62A3E9_1_400004">Smaller Reporting Company</dei:EntityFilerCategory>
  <dei:DocumentFiscalYearFocus contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" id="id_2677847_18886918-561B-406D-A4CA-3FB6868936E9_1_3">2013</dei:DocumentFiscalYearFocus>
  <dei:DocumentType contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" id="id_2677847_18886918-561B-406D-A4CA-3FB6868936E9_1_0">10-Q</dei:DocumentType>
  <dei:DocumentPeriodEndDate contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" id="id_2677847_18886918-561B-406D-A4CA-3FB6868936E9_1_2">2013-06-30</dei:DocumentPeriodEndDate>
  <dei:EntityCentralIndexKey contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" id="id_2677847_F38A9F63-AAA3-4C4C-A1AA-B15C0E62A3E9_1_400002">0001226616</dei:EntityCentralIndexKey>
  <dei:CurrentFiscalYearEndDate contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" id="id_2677847_F38A9F63-AAA3-4C4C-A1AA-B15C0E62A3E9_1_400003">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" id="id_2677847_18886918-561B-406D-A4CA-3FB6868936E9_1_4">Q2</dei:DocumentFiscalPeriodFocus>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" id="id_2677847_D430FBA7-264F-4B5B-8EBF-81CFEF15ECB0_1_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Potentially
dilutive outstanding securities excluded from diluted net loss per
common share because of their anti-dilutive effect:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;
&lt;tr&gt;
&lt;td width="76%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Convertible preferred
stock, as converted&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,200,000&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,200,000&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Stock options&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;3,329,794&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,757,914&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Warrants&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;3,876,067&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,998,686&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Total&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;9,405,861&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;7,956,600&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" id="id_2677847_C8F5AFBB-8CC3-44E8-AF69-F4F03C1CD614_2_4">P5Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" id="id_2677847_DA8FA7A7-49F0-4D36-9758-B5B7D337F5F9_1_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;A summary of
the changes in stock options outstanding during the six months
ended June&amp;#xA0;30, 2013 is as follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;
&lt;tr&gt;
&lt;td width="73%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Stock&lt;br /&gt;
Options&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Weighted&lt;br /&gt;
Average&lt;br /&gt;
Exercise&amp;#xA0;Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Outstanding at
December&amp;#xA0;31, 2012&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;3,328,981&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;4.92&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Granted&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;867,500&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2.83&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Exercised&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;79,462&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2.44&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Cancelled&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;787,225&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2.28&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Outstanding at
June&amp;#xA0;30, 2013&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;3,329,794&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;5.39&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Exercisable at
June&amp;#xA0;30, 2013&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,109,379&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;6.29&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" unitRef="shares" decimals="INF" id="id_2677847_BA131555-A95F-482C-8301-BA2C44423299_3_3">16067</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
  <us-gaap:FairValueMeasurementInputsDisclosureTextBlock contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" id="id_2677847_340C8758-C441-46A2-BFC8-43E67D829A7B_1_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;3. Fair Value
Measurements&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;As defined in
the authoritative guidance for fair value measurements and
disclosures under ASC 820, fair value is based on the price that
would be received to sell an asset or would be paid to transfer a
liability in an orderly transaction between market participants at
the measurement date. To increase the comparability and consistency
of fair value measurements, ASC 820 prescribes a fair value
hierarchy that prioritizes observable and unobservable inputs used
to measure fair value into three broad levels which are described
below:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt;
&lt;tr&gt;
&lt;td width="7%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
&lt;td width="90%"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Level 1:&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Inputs are quoted prices (unadjusted) in active markets
for identical assets or liabilities at the measurement
date.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td height="8"&gt;&lt;/td&gt;
&lt;td height="8" colspan="2"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Level&amp;#xA0;2:&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Inputs are quoted prices for similar items in active
markets or inputs are quoted prices for identical or similar items
in markets that are not active.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td height="8"&gt;&lt;/td&gt;
&lt;td height="8" colspan="2"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Level&amp;#xA0;3:&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Inputs are unobservable due to little or no market data
availability and inputs are usually developed by management or a
third-party which reflect those inputs that a market participant
would use. The fair value hierarchy gives the lowest priority to
Level 3 inputs.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The following
table presents our financial instruments measured at fair value on
a recurring basis classified by the fair value measurements and
disclosures valuation hierarchy (in thousands):&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;
&lt;tr&gt;
&lt;td width="66%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="14" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;As of June&amp;#xA0;30,
2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="10" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Fair&amp;#xA0;Value&amp;#xA0;Measurements&amp;#xA0;Using&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;2&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Cash equivalents&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;678&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;678&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td height="16"&gt;&lt;/td&gt;
&lt;td height="16" colspan="16"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="14" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;As of December 31,
2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="10" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Fair&amp;#xA0;Value&amp;#xA0;Measurements&amp;#xA0;Using&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;2&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Cash equivalents&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,720&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,720&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;At
June&amp;#xA0;30, 2013, cash equivalents (instruments with maturities
of three months or less at the date of purchase) were primarily
invested in money market accounts, the fair value of which is based
on Level 1 criteria in which their carrying amount is a reasonable
estimate of their fair value based on daily quoted market prices.
At June&amp;#xA0;30, 2013 and December&amp;#xA0;31, 2012 we did not hold
financial instruments measured at fair value on a &lt;font style="WHITE-SPACE: nowrap"&gt;non-recurring&lt;/font&gt; basis.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:FairValueMeasurementInputsDisclosureTextBlock>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2677847_69759BC3-912F-4D68-B851-7DE8E80772BD_1_2">2.83</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:EquityMethodInvestmentsDisclosureTextBlock contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" id="id_2677847_959E829B-1491-4AFA-97D3-6A8E19973132_1_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;2. Joint
Venture&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;We entered into
an agreement to form a joint venture company with Zhejiang Medicine
Co., Ltd. and Beijing Make-Friend Medicine Technology Co., Ltd.
effective September&amp;#xA0;27, 2011. The joint venture agreement
provides for the joint venture company, Zhejiang Sunmy &lt;font style="WHITE-SPACE: nowrap"&gt;Bio-Medical&lt;/font&gt; Co., Ltd. (&amp;#x201C;Zhejiang
Sunmy&amp;#x201D;), to develop and commercialize &lt;font style="WHITE-SPACE: nowrap"&gt;MN-221&lt;/font&gt; in China. A sublicense, which
will require the consent of the licensor, will be required for us
to license &lt;font style="WHITE-SPACE: nowrap"&gt;MN-221&lt;/font&gt; to
Zhejiang Sunmy. In accordance with the joint venture agreement, in
March 2012 we paid $680,000 for a 30% interest in Zhejiang Sunmy.
The other parties to the joint venture agreement provided funding
for their combined 70% interest and are responsible for future
funding of Zhejiang Sunmy&amp;#x2019;s activities. We have not entered
into the sublicense of &lt;font style="WHITE-SPACE: nowrap"&gt;MN-221&lt;/font&gt; with Zhejiang Sunmy as of the
date of this report. Zhejiang Sunmy is a variable interest entity
for which we are not the primary beneficiary as we do not have a
majority of the board seats and we will not have power to direct or
significantly influence the actions of the entity. We therefore
account for the activities of Zhejiang Sunmy under the equity
method whereby we absorb any loss or income generated by Zhejiang
Sunmy according to our percentage ownership. At June&amp;#xA0;30, 2013
we reflect a long-term asset on our consolidated balance sheet
which represents our investment in Zhejiang Sunmy, net of our
portion of any generated loss or income.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" unitRef="shares" decimals="INF" id="id_2677847_BA131555-A95F-482C-8301-BA2C44423299_3_4">248511</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
  <us-gaap:RevenueRecognitionDeferredRevenue contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" id="id_2677847_F6CFDDAB-B332-4C4A-BD93-FCCE51F0A822_1_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Revenue Recognition
and Deferred Revenue&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In October
2011, we entered into an agreement with Kissei Pharmaceutical Co.,
Ltd., or Kissei, to perform research and development services
relating to &lt;font style="WHITE-SPACE: nowrap"&gt;MN-221&lt;/font&gt; in
exchange for a &lt;font style="WHITE-SPACE: nowrap"&gt;non-refundable&lt;/font&gt; upfront payment of
$2.5&amp;#xA0;million. Under the terms of the agreement, we are
responsible for all costs to be incurred in the performance of
these services. Certain of these research and development services
were completed in 2012 and the remaining services are expected to
be completed after 2013. We are recognizing the $2.5 million
payment as revenue as the research and development services are
performed. The amount received from Kissei, net of the amount
recorded as revenue to date, is included on the balance sheet as
deferred revenue and will be recognized as revenue as we perform
the remaining services. For the three months ended June&amp;#xA0;30,
2013 and 2012, revenue recorded was $0 and $0.5 million,
respectively. For the six months ended June&amp;#xA0;30, 2013 and 2012,
revenue recorded was $3,257 and $0.7 million,
respectively.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:RevenueRecognitionDeferredRevenue>
  <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" id="id_2677847_9A3348A0-FF64-4753-B4E6-854246C30308_1_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;5. Balance Sheet
Details&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Accrued
Expenses&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Accrued
expenses consist of the following:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;
&lt;tr&gt;
&lt;td width="74%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;br /&gt;
2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Research and development
costs&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;122,714&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;152,046&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Professional services
fees&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;161,920&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;68,102&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Other&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;169,372&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;94,504&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;454,006&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;314,652&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" id="id_2677847_7099F951-832C-439D-A3D9-6F514E27CB6E_1_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The following
table provides the assumptions used in the Black-Scholes valuation
model for the three and six months ended June&amp;#xA0;30, 2013 and
2012. The ESPP assumptions for the three months ended June&amp;#xA0;30,
2013 and 2012 are actual amounts, and for the six months ended
June&amp;#xA0;30, 2013 and 2012 are weighted average
amounts.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt;
&lt;tr&gt;
&lt;td width="36%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;June&amp;#xA0;
30,&amp;#xA0;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;June&amp;#xA0;
30,&amp;#xA0;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Six&amp;#xA0;Months&amp;#xA0;Ended&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;June&amp;#xA0;
30,&amp;#xA0;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Six&amp;#xA0;Months&amp;#xA0;Ended&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;June&amp;#xA0;
30,&amp;#xA0;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Stock Options
assumptions:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Risk-free interest
rate&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.80&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.51&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.80&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.51&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Expected volatility of
common stock&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;86.10&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;78.58&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;86.10&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;78.58&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Dividend yield&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.0&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.0&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.0&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.0&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Expected term
(in&amp;#xA0;years)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;5.5&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;5.0&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;5.5&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;5.0&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;ESPP
assumptions:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Risk-free interest
rate&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.15&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.16&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.18&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.43&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Expected volatility of
common stock&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;91.60&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;74.34&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;91.44&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;76.11&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Dividend yield&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.0&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.0&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.0&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.0&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Expected term
(in&amp;#xA0;years)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.5&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.5&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.5&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.5&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
  <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" id="id_2677847_1298E54B-C741-4380-AAB8-719DB17250C2_1_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 0px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The following
table presents our financial instruments measured at fair value on
a recurring basis classified by the fair value measurements and
disclosures valuation hierarchy (in thousands):&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;
&lt;tr&gt;
&lt;td width="66%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="14" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;As of June&amp;#xA0;30,
2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="10" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Fair&amp;#xA0;Value&amp;#xA0;Measurements&amp;#xA0;Using&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;2&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Cash equivalents&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;678&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;678&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td height="16"&gt;&lt;/td&gt;
&lt;td height="16" colspan="16"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="14" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;As of December 31,
2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="10" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Fair&amp;#xA0;Value&amp;#xA0;Measurements&amp;#xA0;Using&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;2&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Cash equivalents&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,720&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;1,720&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
  <us-gaap:ConsolidationPolicyTextBlock contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" id="id_2677847_06414D61-7919-426C-81DF-381C6F1C7B19_1_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Principles of
Consolidation&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The
consolidated financial statements include the accounts of
MediciNova, Inc. and its wholly-owned subsidiaries. MediciNova,
Inc. and its subsidiaries are collectively referred to herein as
&amp;#x201C;we,&amp;#x201D; &amp;#x201C;our&amp;#x201D; or &amp;#x201C;us.&amp;#x201D;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;On
December&amp;#xA0;13, 2006, MediciNova (Europe) Limited, a wholly-owned
subsidiary of MediciNova, Inc.,&amp;#xA0;was incorporated under the
laws of England and Wales and established for the purpose of
facilitating the clinical development of the Company&amp;#x2019;s
product candidates for the European marketplace. MediciNova
(Europe) Limited&amp;#x2019;s functional currency is the U.S. dollar,
the reporting currency of its parent.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;On
January&amp;#xA0;4, 2007, MediciNova Japan, Inc., a wholly-owned
subsidiary of MediciNova, Inc., was incorporated under the laws of
Japan and established to strengthen business development and
investor and public relations activities in Japan and other Asian
countries. MediciNova Japan, Inc.&amp;#x2019;s functional currency is
the Japanese yen.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;On
August&amp;#xA0;17, 2009, Absolute Merger, Inc., a wholly-owned
subsidiary of MediciNova, Inc. was incorporated under the General
Corporation Law of the State of Delaware for the purpose of
facilitating the acquisition with Avigen.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;All
intercompany transactions and investments in our subsidiaries have
been eliminated in consolidation.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
  <us-gaap:QuarterlyFinancialInformationTextBlock contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" id="id_2677847_9BCF3C11-A9E6-4536-8593-057A60A72D4B_1_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;1. Interim Financial
Information&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;The
Company&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;We were
incorporated in the state of Delaware in September 2000. We are a
development stage biopharmaceutical company focused on acquiring
and developing novel, small molecule therapeutics for the treatment
of serious diseases with unmet medical needs with a specific focus
on the U.S. market. We are currently focusing our development
activities on &lt;font style="WHITE-SPACE: nowrap"&gt;MN-166,&lt;/font&gt; a
drug candidate for the treatment of neurological disorders, and on
&lt;font style="WHITE-SPACE: nowrap"&gt;MN-221,&lt;/font&gt; a drug candidate
for the treatment of acute exacerbations of asthma and chronic
obstructive pulmonary disease, or COPD.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Basis of
Presentation&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;We have
prepared the accompanying unaudited consolidated financial
statements in accordance with accounting principles generally
accepted in the U.S. for interim financial information.
Accordingly, they do not include all of the information and
disclosures required by generally accepted accounting principles
for complete financial statements. In the opinion of management,
all adjustments of a normal recurring nature necessary for the fair
presentation of our financial position, results of operations and
cash flow for the interim periods presented have been included.
Operating results for the three and six months ended June&amp;#xA0;30,
2013 are not necessarily indicative of the results that may be
expected for the year ending December&amp;#xA0;31, 2013 or for any
other period. For further information, see the financial statements
and disclosures thereto for the year ended December&amp;#xA0;31, 2012
in our Annual Report on Form &lt;font style="WHITE-SPACE: nowrap"&gt;10-K&lt;/font&gt; as filed with the Securities and
Exchange Commission on March&amp;#xA0;28, 2013.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Principles of
Consolidation&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The
consolidated financial statements include the accounts of
MediciNova, Inc. and its wholly-owned subsidiaries. MediciNova,
Inc. and its subsidiaries are collectively referred to herein as
&amp;#x201C;we,&amp;#x201D; &amp;#x201C;our&amp;#x201D; or &amp;#x201C;us.&amp;#x201D;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;On
December&amp;#xA0;13, 2006, MediciNova (Europe) Limited, a wholly-owned
subsidiary of MediciNova, Inc.,&amp;#xA0;was incorporated under the
laws of England and Wales and established for the purpose of
facilitating the clinical development of the Company&amp;#x2019;s
product candidates for the European marketplace. MediciNova
(Europe) Limited&amp;#x2019;s functional currency is the U.S. dollar,
the reporting currency of its parent.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;On
January&amp;#xA0;4, 2007, MediciNova Japan, Inc., a wholly-owned
subsidiary of MediciNova, Inc., was incorporated under the laws of
Japan and established to strengthen business development and
investor and public relations activities in Japan and other Asian
countries. MediciNova Japan, Inc.&amp;#x2019;s functional currency is
the Japanese yen.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;On
August&amp;#xA0;17, 2009, Absolute Merger, Inc., a wholly-owned
subsidiary of MediciNova, Inc. was incorporated under the General
Corporation Law of the State of Delaware for the purpose of
facilitating the acquisition with Avigen.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;All
intercompany transactions and investments in our subsidiaries have
been eliminated in consolidation.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Use of
Estimates&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The preparation
of consolidated financial statements in conformity with U.S.
generally accepted accounting principles requires management to
make estimates and assumptions that affect the amounts reported in
the financial statements and accompanying notes. Actual results may
differ from these estimates.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Revenue Recognition
and Deferred Revenue&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In October
2011, we entered into an agreement with Kissei Pharmaceutical Co.,
Ltd., or Kissei, to perform research and development services
relating to &lt;font style="WHITE-SPACE: nowrap"&gt;MN-221&lt;/font&gt; in
exchange for a &lt;font style="WHITE-SPACE: nowrap"&gt;non-refundable&lt;/font&gt; upfront payment of
$2.5&amp;#xA0;million. Under the terms of the agreement, we are
responsible for all costs to be incurred in the performance of
these services. Certain of these research and development services
were completed in 2012 and the remaining services are expected to
be completed after 2013. We are recognizing the $2.5 million
payment as revenue as the research and development services are
performed. The amount received from Kissei, net of the amount
recorded as revenue to date, is included on the balance sheet as
deferred revenue and will be recognized as revenue as we perform
the remaining services. For the three months ended June&amp;#xA0;30,
2013 and 2012, revenue recorded was $0 and $0.5 million,
respectively. For the six months ended June&amp;#xA0;30, 2013 and 2012,
revenue recorded was $3,257 and $0.7 million,
respectively.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Concentrations and
Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;We maintain
cash balances at various financial institutions and such balances
commonly exceed the $250,000 insured amount by the Federal Deposit
Insurance Corporation. We also maintain money market funds at
various financial institutions which are not federally insured,
although they are invested primarily in U.S.&amp;#xA0;government
securities. We have not experienced any losses in such accounts and
management believes that we do not have significant credit risk
with respect to such cash and cash equivalents.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
  <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" id="id_2677847_BA256895-41DB-4590-ACB2-358AE5A4E91F_1_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Accrued
expenses consist of the following:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;
&lt;tr&gt;
&lt;td width="74%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;br /&gt;
2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Research and development
costs&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;122,714&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;152,046&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Professional services
fees&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;161,920&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;68,102&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Other&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;169,372&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;94,504&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;454,006&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;314,652&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" unitRef="shares" decimals="INF" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_3_18">19002419</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" id="id_2677847_A2B65FA2-423E-4885-A2B4-5EA833E676BC_1_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;10. Stockholders&amp;#x2019;
Equity&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Stock
Options&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;We have granted
stock options to our employees, officers, directors and consultants
under the MediciNova, Inc. Amended and Restated 2004 Stock
Incentive Plan, and future stock option grants will be made under
the MediciNova, Inc. 2013 Equity Incentive Plan. A summary of the
changes in stock options outstanding during the six months ended
June&amp;#xA0;30, 2013 is as follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;
&lt;tr&gt;
&lt;td width="73%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Stock&lt;br /&gt;
Options&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Weighted&lt;br /&gt;
Average&lt;br /&gt;
Exercise&amp;#xA0;Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Outstanding at
December&amp;#xA0;31, 2012&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;3,328,981&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;4.92&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Granted&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;867,500&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2.83&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Exercised&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;79,462&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2.44&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Cancelled&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;787,225&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2.28&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Outstanding at
June&amp;#xA0;30, 2013&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;3,329,794&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;5.39&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Exercisable at
June&amp;#xA0;30, 2013&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,109,379&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;6.29&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The aggregate
intrinsic value of stock options outstanding, options exercised and
options exercisable at June&amp;#xA0;30, 2013 was approximately
$209,000, $64,000 and $171,000, respectively. The weighted average
contractual life of options outstanding at June&amp;#xA0;30, 2013 was
7.0 years and the weighted average contractual life of exercisable
options at June&amp;#xA0;30, 2013 was 5.7 years.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Kissei Stock
Purchase&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In
October&amp;#xA0;2011, pursuant to a stock purchase agreement by and
between us and Kissei Pharmaceutical Co. Ltd, or Kissei, Kissei
purchased for $7.5 million (i)&amp;#xA0;an aggregate of 800,000 shares
of our common stock, par value $0.001 per share, at a price of
$2.50 per share, which approximated the fair value of our common
stock at the time of the transaction, and (ii)&amp;#xA0;220,000 shares
of our Series&amp;#xA0;B Convertible Preferred Stock, or Series B
Preferred, par value $0.01 per share, at a price of $25.00 per
share, which approximated the fair value of our preferred stock on
an as converted basis at the time of the transaction. The purchase
agreement contains customary representations, warranties and
covenants and a standstill agreement from Kissei that terminates if
Kissei beneficially owns less than three percent of our outstanding
voting stock. Each share of the Series B Preferred is convertible
into 10&amp;#xA0;shares of common stock. The Series B Preferred ranks
pari passu (on an &lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;as-if-converted-to-common-stock&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;
basis) with the common stock in liquidation and dividend rights.
The holders of the Series B Preferred do not have voting rights,
and the consent of a majority of the outstanding Series B Preferred
is required for certain actions of the Company.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Common Stock Purchase
Agreement&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;On
August&amp;#xA0;20, 2012, we entered into a common stock purchase
agreement with Aspire Capital Fund LLC, or Aspire, pursuant to
which the Company may sell to Aspire, and Aspire would be obligated
to purchase, up to an aggregate of $20 million of our common stock
over the two year term of the agreement, including $1 million in
common stock purchased by Aspire in connection with execution of
the agreement. Periodic sales of our common stock to Aspire are
subject to certain limitations and the per share sales price is
based on closing stock prices at or near each transaction date. No
more than 3,231,096 shares of our common stock can be issued under
this agreement, including the 363,636 shares initially issued to
Aspire in consideration of entering into the agreement. Our
proceeds will depend on the frequency and number of shares of our
common stock sold to Aspire and the per share purchase price of
each transaction. We may on any business day over term of the
agreement direct Aspire to purchase up to 50,000 shares, to a
maximum of $500,000 per business day. The purchase price shall be
the lower of the lowest sale price of the Company&amp;#x2019;s common
stock on the date of the sale, or the average of the three lowest
closing stock prices during the 12 consecutive business days ending
on the business day immediately preceding the purchase date. In
addition, MediciNova may on any business day over the term of the
Agreement direct Aspire to make a volume-weighted average purchase
(&amp;#x201C;VWAP&amp;#x201D;) of stock not to exceed 15% (which limitation
may be increased up to 30% by the mutual agreement of the parties)
of the aggregate shares of our stock traded on the next business
day, the purchase price of which shall be the lower of the closing
price on the date of the sale, or 95% of the next business
day&amp;#x2019;s Nasdaq volume weighted average price, subject to a
minimum market price threshold established by us and certain other
exceptions. The agreement provides Aspire certain termination
rights, including rights under an event of default as defined
therein, under which the Company may not require and Aspire would
not be obligated to purchase any shares of our common stock. The
Company and Aspire may also not effect any sales under the
agreement on any purchase date where the closing price of our
common stock is less than $1.00 per share. In addition to the
initial issuance of shares, as of June&amp;#xA0;30, 2013 the Company
had completed sales to Aspire totaling 2,454,532 shares of common
stock at prices ranging from $1.60 to $3.82 per share, generating
gross proceeds of $5.3 million. The Company has made no sales of
our common to stock to Aspire subsequent to June&amp;#xA0;30, 2013
through the date of this report.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Issuance of
Warrant&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;On
August&amp;#xA0;22, 2012, we issued a warrant in exchange for investor
relations services to purchase up to 130,000 of our common shares
at a price of $1.88 per share, the closing price of our common
stock on that date. The warrant contains provisions whereby the
warrant becomes exercisable for specified shares of our common
stock as a result of our stock achieving certain share price
targets within a 15 month period beginning on August&amp;#xA0;22, 2012.
The warrant expires in five years. The warrant is valued at its
fair value of approximately $0.1&amp;#xA0;million on August&amp;#xA0;22,
2012, is classified as equity and as a prepaid expense, and is
being amortized over the one year period beginning August&amp;#xA0;22,
2012.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Exercise of
Warrants&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;During the
three and six months ended June&amp;#xA0;30, 2013, 121,666 warrants
related to the March&amp;#xA0;23, 2011 public offering of 2,750,000
units, with each unit consisting of one share of common stock and
one warrant, were exercised generating proceeds of $0.4 million. No
warrants were exercised during the three and six months ended
June&amp;#xA0;30, 2012.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;At-The-Market&lt;/font&gt;&lt;/font&gt; Equity
Distribution Agreement&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;On
April&amp;#xA0;17, 2013, we entered into an &lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;at-the-market&lt;/font&gt;&lt;/font&gt; equity
distribution agreement with Macquarie Capital (USA) Inc., or MCUSA,
pursuant to which the Company may from time to time sell through
MCUSA, acting as our sales agent, shares of our common stock up to
an aggregate offering price of $6 million. Unless mutually agreed
otherwise, no sale of an amount of shares of our common stock may
be greater than the lower of $50,000 and 10% of the lower of the
&lt;font style="WHITE-SPACE: nowrap"&gt;5-day&lt;/font&gt; or &lt;font style="WHITE-SPACE: nowrap"&gt;3-month&lt;/font&gt; average daily traded value of
our common stock as reported by Bloomberg as of the date of the
applicable issuance notice, and the price per share may not be less
than the greater of $1.19 or the last available closing price of a
share of common stock on The Nasdaq Global Market. MCUSA will use
its commercially reasonable efforts consistent with its customary
trading and sales practices and applicable laws, rules and
regulations to sell shares of our common stock and may sell such
shares by any method permitted by law deemed to be &amp;#x201C;at the
market&amp;#x201D;. We will pay MCUSA an aggregate commission rate of
8.0% of the gross proceeds of any common stock sold through MCUSA
under the agreement. Our proceeds will depend on the number of
shares of our common stock sold to MCUSA and the per share purchase
price of each transaction. The agreement with MCUSA provides both
MCUSA and the Company the right to terminate the agreement in its
sole discretion upon giving five business days written notice. As
of June&amp;#xA0;30, 2013, the Company had completed sales to Macquarie
totaling 1,770,971 shares of common stock at prices ranging from
$2.44 to $4.10 per share, generating gross proceeds of $5.6
million.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Securities Purchase
Agreement&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;On May&amp;#xA0;9,
2013, we entered into a Securities Purchase Agreement with certain
institutional and accredited investors (the &amp;#x201C;Purchase
Agreement&amp;#x201D;) pursuant to which we agreed to sell to the
investors 1,158,730 shares of our common stock at a price of $3.15
per share and warrants to purchase an aggregate of 869,047 shares
of our common stock with an exercise price of $3.15 per share (the
&amp;#x201C;Private Placement&amp;#x201D;). The Private Placement closed on
May&amp;#xA0;14, 2013. The warrants will expire on May&amp;#xA0;9, 2018 and
may be exercised for cash or, if the current market price of our
common stock is greater than the per share exercise price, by
surrender of a portion of the warrant in a cashless exercise. The
aggregate purchase price for the shares and the warrants sold in
the Private Placement was $3.7 million and associated expenses
incurred were $0.3 million. The Purchase Agreement includes
representations, warranties, covenants and closing conditions
customary for transactions of this type.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In connection
with the purchase by one investor of 158,730 shares of our common
stock and a warrant to purchase 119,047 shares of our common stock,
on May&amp;#xA0;29, 2013 the investor provided $51,389 additional
consideration for the shares and the warrant, and the investor and
the Company entered into an amendment to the warrant to reflect an
exercise price of $3.38 per share.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The net
proceeds for the shares and the warrants sold in the Private
Placement of $3.4 million were allocated by the Company based on
the relative fair value of each instrument. The Company determined
the fair value of the shares based on the closing price of our
common stock on May&amp;#xA0;9, 2013, and the fair value of the
warrants based on a Black-Scholes valuation model.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_1_16">-4718902</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:EarningsPerShareTextBlock contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" id="id_2677847_9DFEF7C8-1FA0-4E8F-AE6F-B44981FDEEE5_1_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;4. Net Loss Per
Share&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Net loss per
common share is presented as basic and diluted net loss per common
share. Basic net loss per common share is calculated by dividing
the net loss attributable to common stockholders by the weighted
average number of common shares outstanding for the period, without
consideration for common stock equivalents. Diluted net loss per
common share is calculated by dividing the net loss attributable to
common stockholders by the weighted average number of common shares
outstanding for the period using the treasury-stock method. For
purposes of this calculation, convertible preferred stock, stock
options and warrants are considered to be common stock equivalents
and are only included in the calculation of diluted net loss per
common share when their effect is dilutive.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Potentially
dilutive outstanding securities excluded from diluted net loss per
common share because of their anti-dilutive effect:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;
&lt;tr&gt;
&lt;td width="76%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Convertible preferred
stock, as converted&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,200,000&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,200,000&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Stock options&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;3,329,794&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,757,914&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Warrants&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;3,876,067&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,998,686&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Total&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;9,405,861&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;7,956,600&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" unitRef="shares" decimals="INF" id="id_2677847_F2CBBBB1-EF2F-453A-B8CA-07DCF638AB21_3_3">79462</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ConcentrationRiskCreditRisk contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" id="id_2677847_FCC417A9-D86F-4C54-B4DF-7358FDDE5414_1_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Concentrations and
Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;We maintain
cash balances at various financial institutions and such balances
commonly exceed the $250,000 insured amount by the Federal Deposit
Insurance Corporation. We also maintain money market funds at
various financial institutions which are not federally insured,
although they are invested primarily in U.S.&amp;#xA0;government
securities. We have not experienced any losses in such accounts and
management believes that we do not have significant credit risk
with respect to such cash and cash equivalents.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" id="id_2677847_1423E34B-DF8C-431B-989D-7AF7263F9B5A_1_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;8. Related Party
Transactions&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;On May&amp;#xA0;9,
2013, the Company entered into a Securities Purchase Agreement with
certain institutional and accredited investors pursuant to which we
agreed to sell to the investors 1,158,730 shares of our common
stock and warrants to purchase an aggregate of 869,047 shares of
our common stock (the &amp;#x201C;Private Placement&amp;#x201D;). The Private
Placement closed on May&amp;#xA0;14, 2013. The Private Placement
included the issuance by the Company of shares of common stock and
a warrant to purchase shares of common stock to Fountain Erika LLC
(&amp;#x201C;Fountain Erika&amp;#x201D;), an entity of which Tatsuo Izumi, a
member of the Company&amp;#x2019;s board of directors, is a principal.
Fountain Erika&amp;#x2019;s acquisition of the shares of the
Company&amp;#x2019;s common stock and a warrant to purchase shares of
the Company&amp;#x2019;s common stock was at an &amp;#x201C;at the
market&amp;#x201D; price.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2677847_69759BC3-912F-4D68-B851-7DE8E80772BD_1_4">2.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" unitRef="shares" decimals="INF" id="id_2677847_E9B8A637-0905-4145-A2C7-7F4ED0B1E977_1_3">9405861</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:UseOfEstimates contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" id="id_2677847_F863EA4D-1EBD-4235-BFED-9D1A1DA44A87_1_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Use of
Estimates&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The preparation
of consolidated financial statements in conformity with U.S.
generally accepted accounting principles requires management to
make estimates and assumptions that affect the amounts reported in
the financial statements and accompanying notes. Actual results may
differ from these estimates.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_3_17">-0.27</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2677847_69759BC3-912F-4D68-B851-7DE8E80772BD_1_3">2.44</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" unitRef="shares" decimals="INF" id="id_2677847_E33F0F93-E85E-4509-8267-7BC998C714AD_2_0">867500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:SubsequentEventsTextBlock contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" id="id_2677847_13E8016B-7928-41C3-AD8B-672E770A69B5_1_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;11. Subsequent
Events&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Proceeds From Sales
of Common Stock&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Between
July&amp;#xA0;1, 2013 and the date of this report, we have generated
net proceeds of $0.4&amp;#xA0;million under the &lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;at-the-market&lt;/font&gt;&lt;/font&gt; equity
distribution agreement with MCUSA on the sale of 165,266 shares of
our common stock. As of the date of this report, gross sales of our
common stock through MCUSA aggregated $6.0 million and we therefore
have no remaining available balance under the agreement with
MCUSA.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" id="id_2677847_F2CBBBB1-EF2F-453A-B8CA-07DCF638AB21_3_6">P1Y5M9D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:DeferredRevenuePeriodIncreaseDecrease contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_1_4">-3257</us-gaap:DeferredRevenuePeriodIncreaseDecrease>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" id="id_2677847_D300E5A1-BF4D-4955-8603-93BC0EF53D25_1_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;7. Income
Taxes&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In accordance
with the authoritative guidance for income taxes under ASC 740, a
deferred tax asset or liability is determined based on the
difference between the financial statements and the tax basis of
assets and liabilities as measured by the enacted tax rates, which
will be in effect when these differences reverse. We provide a
valuation allowance against net deferred assets unless, based upon
the available evidence, it is more likely than not that the
deferred tax assets will be realized.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company
recognizes the impact of a tax position in the financial statements
only if that position is more likely than not of being sustained
upon examination by taxing authorities, based on the technical
merits of the position. Our practice is to recognize interest
and/or penalties related to income tax matters in income tax
expense.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;We are subject
to taxation in the U.S., California and foreign jurisdictions, of
which currently no years are under examination. Our tax years for
2000 and forward are subject to examination by the U.S. and state
tax authorities due to the carry-forward of unutilized net
operating losses and research and development credits. During the
three and six months ended June&amp;#xA0;30, 2013 and 2012, income tax
expense related to intercompany service income earned by our
Japanese subsidiary, MediciNova Japan, Inc.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" unitRef="shares" decimals="INF" id="id_2677847_E23DA0B0-021D-48D2-B4F7-69A00A6528BF_1_400004">787225</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" id="id_2677847_0F4BB207-FE0B-4D16-AEBF-C71BC0C0B9F6_1_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Basis of
Presentation&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;We have
prepared the accompanying unaudited consolidated financial
statements in accordance with accounting principles generally
accepted in the U.S. for interim financial information.
Accordingly, they do not include all of the information and
disclosures required by generally accepted accounting principles
for complete financial statements. In the opinion of management,
all adjustments of a normal recurring nature necessary for the fair
presentation of our financial position, results of operations and
cash flow for the interim periods presented have been included.
Operating results for the three and six months ended June&amp;#xA0;30,
2013 are not necessarily indicative of the results that may be
expected for the year ending December&amp;#xA0;31, 2013 or for any
other period. For further information, see the financial statements
and disclosures thereto for the year ended December&amp;#xA0;31, 2012
in our Annual Report on Form &lt;font style="WHITE-SPACE: nowrap"&gt;10-K&lt;/font&gt; as filed with the Securities and
Exchange Commission on March&amp;#xA0;28, 2013.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" id="id_2677847_C8F5AFBB-8CC3-44E8-AF69-F4F03C1CD614_2_3">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" id="id_2677847_F2AB6BFF-250E-4FD0-B9AA-A0E541C64A56_1_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;6. Stock-Based
Compensation&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;For the three
months ended June&amp;#xA0;30, 2013 and 2012, stock-based compensation
expense (or credit) related to stock options and the employee stock
purchase plan was approximately $364,000 and $(566,000),
respectively, and was recorded as a component of general and
administrative expense (approximately $234,000 and $(432,000),
respectively) and research and development expense (approximately
$130,000 and $(134,000), respectively). For the six months ended
June&amp;#xA0;30, 2013 and 2012, stock-based compensation expense
related to stock options and the employee stock purchase plan was
approximately $521,000 and $362,000, respectively, and was recorded
as a component of general and administrative expense (approximately
$326,000 and $214,000, respectively) and research and development
expense (approximately $195,000 and $148,000, respectively). During
the three months ended June&amp;#xA0;30, 2013 and 2012, 38,085 and
60,000 stock options, respectively, were exercised from which
proceeds of approximately $92,000 and $138,000, respectively, were
received. During the six months ended June&amp;#xA0;30, 2013 and 2012,
79,462 and 60,000 stock options, respectively, were exercised from
which proceeds of approximately $194,000 and $138,000,
respectively, were received. As of June&amp;#xA0;30, 2013, there was
$2.2 million of unamortized compensation expense related to
unvested stock option awards which is expected to be recognized
over a remaining weighted-average vesting period of 1.44
years.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;During the
three and six months ended June&amp;#xA0;30, 2013, options to purchase
867,500 shares of common stock were granted. During the three and
six months ended June&amp;#xA0;30, 2012, options to purchase 15,000
shares of common stock were granted. As share-based compensation
expense recognized in the accompanying consolidated statements of
operations and comprehensive loss included expense related to stock
option awards ultimately expected to vest, such expense should be
reduced for estimated forfeitures. The authoritative guidance for
compensation expense requires forfeitures to be estimated at the
time of grant and revised, if necessary, in subsequent periods if
actual forfeitures differ from those estimates. As forfeitures have
been immaterial in the past and are expected to continue to be
immaterial, we did not estimate any forfeitures during 2012, or
during the six months ended June&amp;#xA0;30, 2013. We will adjust our
stock-based compensation expense when any forfeitures
occur.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The MediciNova,
Inc. 2007 Employee Stock Purchase Plan, or ESPP, provides employees
the right to purchase our common stock through payroll deductions
(not to exceed 15% of each employee&amp;#x2019;s compensation) at the
lower of 85% of fair market value at the beginning of or the end of
each &lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt; offering
period. For the three and six months ended June&amp;#xA0;30, 2013, the
number of shares of common stock issued under the ESPP was 16,067
and for the three and six months ended June&amp;#xA0;30, 2012, the
number of shares of common stock issued under the ESPP was 15,550.
Shares of common stock available for future ESPP issuances at
June&amp;#xA0;30, 2013 and 2012 were 248,511 and 269,442,
respectively.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company
uses the Black-Scholes valuation model for determining the
estimated fair value and the stock-based compensation for
stock-based awards to employees. The following table provides the
assumptions used in the Black-Scholes valuation model for the three
and six months ended June&amp;#xA0;30, 2013 and 2012. The ESPP
assumptions for the three months ended June&amp;#xA0;30, 2013 and 2012
are actual amounts, and for the six months ended June&amp;#xA0;30, 2013
and 2012 are weighted average amounts.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt;
&lt;tr&gt;
&lt;td width="36%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="13%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;June&amp;#xA0;
30,&amp;#xA0;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;June&amp;#xA0;
30,&amp;#xA0;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Six&amp;#xA0;Months&amp;#xA0;Ended&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;June&amp;#xA0;
30,&amp;#xA0;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Six&amp;#xA0;Months&amp;#xA0;Ended&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;June&amp;#xA0;
30,&amp;#xA0;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Stock Options
assumptions:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Risk-free interest
rate&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.80&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.51&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.80&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.51&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Expected volatility of
common stock&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;86.10&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;78.58&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;86.10&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;78.58&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Dividend yield&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.0&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.0&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.0&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.0&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Expected term
(in&amp;#xA0;years)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;5.5&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;5.0&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;5.5&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;5.0&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;ESPP
assumptions:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Risk-free interest
rate&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.15&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.16&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.18&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.43&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Expected volatility of
common stock&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;91.60&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;74.34&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;91.44&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;76.11&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Dividend yield&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.0&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.0&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.0&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.0&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Expected term
(in&amp;#xA0;years)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.5&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.5&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.5&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0.5&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" id="id_2677847_FE981FDB-4AFE-4E75-B8E6-72C2707B41EA_1_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;9. Commitments and
Contingencies&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Legal
Proceedings&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;On July&amp;#xA0;8,
2011, a former employee filed a lawsuit in the Superior Court of
the State of California, County of San Diego, asserting certain
claims related to the Company&amp;#x2019;s work environment and the
employee&amp;#x2019;s termination, and on December&amp;#xA0;12, 2011 the
court granted our motion to compel arbitration. On January&amp;#xA0;11,
2013 we filed a motion for dismissal and for monetary sanctions. On
April&amp;#xA0;30, 2013 the arbitrator dismissed this action and
awarded monetary sanctions to the Company of approximately
$100,000.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;We are not
involved in any legal proceedings as of June&amp;#xA0;30, 2013. We may
become involved in various other disputes and legal proceedings
which arise in the ordinary course of business. Our assessment of
the likely impact of our pending litigation may change over time.
An adverse result in any of these matters may occur which could
harm our business and result in a material liability.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_1_21">44322</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BD5FAE21-42B4-4A69-8B8B-3F39112EEBE5_4_1">3257</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
  <us-gaap:OtherNonoperatingIncome contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_3_10">6517</us-gaap:OtherNonoperatingIncome>
  <us-gaap:IncomeTaxesPaid contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_1_43">2745</us-gaap:IncomeTaxesPaid>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_3_16">-5205043</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_3_11">-5204499</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_3_21">-10637</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
  <us-gaap:Revenues contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_3_0">3257</us-gaap:Revenues>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_1_11">118567</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_3_22">-5215680</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_3_6">-5205491</us-gaap:OperatingIncomeLoss>
  <us-gaap:GainLossOnDispositionOfAssets contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_1_8">4800</us-gaap:GainLossOnDispositionOfAssets>
  <us-gaap:NetIncomeLoss contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_3_13">-5205043</us-gaap:NetIncomeLoss>
  <us-gaap:OtherNonoperatingExpense contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_3_8">5525</us-gaap:OtherNonoperatingExpense>
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_1_13">262686</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_3_4">3566671</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_1_34">12765374</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_1_3">521286</us-gaap:ShareBasedCompensation>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_1_35">8006950</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:OperatingExpenses contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_3_5">5208748</us-gaap:OperatingExpenses>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_3_12">544</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:ProceedsFromWarrantExercises contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-5" id="id_2677847_CAFC5452-4A4E-45FC-95E8-A251AC1FF285_3_3">400000</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_C8F5AFBB-8CC3-44E8-AF69-F4F03C1CD614_2_1">64000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_1_26">12758677</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_1_23">4800</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_F2CBBBB1-EF2F-453A-B8CA-07DCF638AB21_3_4">194000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_1_5">67282</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_1_24">-39522</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_3_3">1642077</us-gaap:ResearchAndDevelopmentExpense>
  <mnov:ProceedsOrPaymentsForIssuanceOrRepurchaseOfCommonStockNet contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_1_31">6697</mnov:ProceedsOrPaymentsForIssuanceOrRepurchaseOfCommonStockNet>
  <mnov:WarrantsExercised contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" unitRef="shares" decimals="0" id="id_2677847_CAFC5452-4A4E-45FC-95E8-A251AC1FF285_3_1">121666</mnov:WarrantsExercised>
  <mnov:IncreaseDecreaseInAccountsPayableAccruedExpensesIncomeTaxesPayableAndDeferredRent contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_1_12">-238489</mnov:IncreaseDecreaseInAccountsPayableAccruedExpensesIncomeTaxesPayableAndDeferredRent>
  <mnov:ProceedsFromIssuanceOfPrivatePlacementNet contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-5" id="id_2677847_7931FE15-0886-4BFF-98B7-806D9BC2B8D1_1_0">3400000</mnov:ProceedsFromIssuanceOfPrivatePlacementNet>
  <mnov:ProceedsFromIssuanceOfCommonStockGross contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0_705999x732135" unitRef="iso4217_USD" decimals="-5" id="id_2677847_A831F5F0-3A20-47CD-8BBF-F107A24FDC9E_1001_2">6000000</mnov:ProceedsFromIssuanceOfCommonStockGross>
  <us-gaap:EquityIssuancePerShareAmount contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0_705999x732135_711502x711169_734171x806301" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2677847_E4116147-5666-4500-819F-F07D0ADDBCB6_1003_6">2.44</us-gaap:EquityIssuancePerShareAmount>
  <us-gaap:EquityIssuancePerShareAmount contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0_705999x732135_711502x716112_734171x806301" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2677847_E4116147-5666-4500-819F-F07D0ADDBCB6_2003_7">4.10</us-gaap:EquityIssuancePerShareAmount>
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForCash contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0_705999x732135_734171x806301" unitRef="shares" decimals="0" id="id_2677847_E4116147-5666-4500-819F-F07D0ADDBCB6_3003_5">1770971</us-gaap:StockIssuedDuringPeriodSharesIssuedForCash>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0_705999x732135_734171x806301" unitRef="iso4217_USD" decimals="-5" id="id_2677847_E4116147-5666-4500-819F-F07D0ADDBCB6_3003_8">5600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:EquityIssuancePerShareAmount contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0_705999x827742_709650x713713_711502x711169_734171x796264" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2677847_9CF8DC32-C639-4465-AAAF-4A3E5A13BD94_1002_13">1.60</us-gaap:EquityIssuancePerShareAmount>
  <us-gaap:EquityIssuancePerShareAmount contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0_705999x827742_709650x713713_711502x716112_734171x796264" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2677847_9CF8DC32-C639-4465-AAAF-4A3E5A13BD94_2002_14">3.82</us-gaap:EquityIssuancePerShareAmount>
  <mnov:ClosingPriceOfCommonStock contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0_705999x827742_709650x713713_711502x716112_734171x796264" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2677847_9CF8DC32-C639-4465-AAAF-4A3E5A13BD94_2002_16">1.00</mnov:ClosingPriceOfCommonStock>
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForCash contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0_705999x827742_709650x713713_734171x796264" unitRef="shares" decimals="0" id="id_2677847_9CF8DC32-C639-4465-AAAF-4A3E5A13BD94_3002_12">2454532</us-gaap:StockIssuedDuringPeriodSharesIssuedForCash>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0_705999x827742_709650x713713_734171x796264" unitRef="iso4217_USD" decimals="-5" id="id_2677847_9CF8DC32-C639-4465-AAAF-4A3E5A13BD94_3002_15">5300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0_712080x710630" unitRef="iso4217_USD" decimals="0" id="id_2677847_F2CBBBB1-EF2F-453A-B8CA-07DCF638AB21_1003_1">326000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0_712080x713040" unitRef="iso4217_USD" decimals="0" id="id_2677847_F2CBBBB1-EF2F-453A-B8CA-07DCF638AB21_2003_2">195000</us-gaap:ShareBasedCompensation>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0_712382x708980" unitRef="shares" decimals="INF" id="id_2677847_E9B8A637-0905-4145-A2C7-7F4ED0B1E977_1001_1">3329794</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0_712382x710593" unitRef="shares" decimals="INF" id="id_2677847_E9B8A637-0905-4145-A2C7-7F4ED0B1E977_2001_0">2200000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0_712382x715581" unitRef="shares" decimals="INF" id="id_2677847_E9B8A637-0905-4145-A2C7-7F4ED0B1E977_3001_2">3876067</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0_713115x808458" unitRef="iso4217_USD" decimals="0" id="id_2677847_F2CBBBB1-EF2F-453A-B8CA-07DCF638AB21_3003_0">521000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0_716413x708980" unitRef="pure" decimals="4" id="id_2677847_ED8E0284-3349-4777-A252-B1EAC47E6111_1003_1">0.0080</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0_716413x708980" unitRef="pure" decimals="4" id="id_2677847_ED8E0284-3349-4777-A252-B1EAC47E6111_1003_2">0.8610</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0_716413x708980" id="id_2677847_ED8E0284-3349-4777-A252-B1EAC47E6111_1003_4">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0_716413x708980" unitRef="pure" decimals="3" id="id_2677847_ED8E0284-3349-4777-A252-B1EAC47E6111_1003_3">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0_716413x715677" unitRef="pure" decimals="4" id="id_2677847_ED8E0284-3349-4777-A252-B1EAC47E6111_2003_6">0.0018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0_716413x715677" unitRef="pure" decimals="4" id="id_2677847_ED8E0284-3349-4777-A252-B1EAC47E6111_2003_7">0.9144</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0_716413x715677" id="id_2677847_ED8E0284-3349-4777-A252-B1EAC47E6111_2003_9">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE402953--1310-Q0008_STD_181_20130630_0_716413x715677" unitRef="pure" decimals="3" id="id_2677847_ED8E0284-3349-4777-A252-B1EAC47E6111_2003_8">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod contextRef="eol_PE402953--1310-Q0008_STD_182_20120630_0" unitRef="shares" decimals="INF" id="id_2677847_BA131555-A95F-482C-8301-BA2C44423299_5_3">15550</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward contextRef="eol_PE402953--1310-Q0008_STD_182_20120630_0" unitRef="shares" decimals="INF" id="id_2677847_BA131555-A95F-482C-8301-BA2C44423299_5_4">269442</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE402953--1310-Q0008_STD_182_20120630_0" unitRef="shares" decimals="INF" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_4_18">16115570</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE402953--1310-Q0008_STD_182_20120630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_2_16">-7270877</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE402953--1310-Q0008_STD_182_20120630_0" unitRef="shares" decimals="INF" id="id_2677847_F2CBBBB1-EF2F-453A-B8CA-07DCF638AB21_4_3">60000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE402953--1310-Q0008_STD_182_20120630_0" unitRef="shares" decimals="INF" id="id_2677847_E9B8A637-0905-4145-A2C7-7F4ED0B1E977_2_3">7956600</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE402953--1310-Q0008_STD_182_20120630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_4_17">-0.38</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="eol_PE402953--1310-Q0008_STD_182_20120630_0" unitRef="shares" decimals="INF" id="id_2677847_E33F0F93-E85E-4509-8267-7BC998C714AD_4_0">15000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:DeferredRevenuePeriodIncreaseDecrease contextRef="eol_PE402953--1310-Q0008_STD_182_20120630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_2_4">-684797</us-gaap:DeferredRevenuePeriodIncreaseDecrease>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE402953--1310-Q0008_STD_182_20120630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_2_21">49336</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned contextRef="eol_PE402953--1310-Q0008_STD_182_20120630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BD5FAE21-42B4-4A69-8B8B-3F39112EEBE5_5_1">700000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
  <us-gaap:OtherNonoperatingIncome contextRef="eol_PE402953--1310-Q0008_STD_182_20120630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_4_10">17937</us-gaap:OtherNonoperatingIncome>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE402953--1310-Q0008_STD_182_20120630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_4_16">-6148573</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:PaymentsToAcquireInterestInJointVenture contextRef="eol_PE402953--1310-Q0008_STD_182_20120630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_2_22">680000</us-gaap:PaymentsToAcquireInterestInJointVenture>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="eol_PE402953--1310-Q0008_STD_182_20120630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_4_11">-6148573</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="eol_PE402953--1310-Q0008_STD_182_20120630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_4_21">-4883</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
  <us-gaap:Revenues contextRef="eol_PE402953--1310-Q0008_STD_182_20120630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_4_0">684797</us-gaap:Revenues>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE402953--1310-Q0008_STD_182_20120630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_2_11">19888</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE402953--1310-Q0008_STD_182_20120630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_4_22">-6153456</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE402953--1310-Q0008_STD_182_20120630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_4_6">-6161463</us-gaap:OperatingIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="eol_PE402953--1310-Q0008_STD_182_20120630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_4_13">-6148573</us-gaap:NetIncomeLoss>
  <us-gaap:OtherNonoperatingExpense contextRef="eol_PE402953--1310-Q0008_STD_182_20120630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_4_8">5047</us-gaap:OtherNonoperatingExpense>
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="eol_PE402953--1310-Q0008_STD_182_20120630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_2_13">-389771</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE402953--1310-Q0008_STD_182_20120630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_4_4">3483860</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE402953--1310-Q0008_STD_182_20120630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_2_34">165619</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE402953--1310-Q0008_STD_182_20120630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_2_3">361521</us-gaap:ShareBasedCompensation>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE402953--1310-Q0008_STD_182_20120630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_2_35">-7834594</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:OperatingExpenses contextRef="eol_PE402953--1310-Q0008_STD_182_20120630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_4_5">6846260</us-gaap:OperatingExpenses>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE402953--1310-Q0008_STD_182_20120630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_2_26">137730</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="eol_PE402953--1310-Q0008_STD_182_20120630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_F2CBBBB1-EF2F-453A-B8CA-07DCF638AB21_4_4">138000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE402953--1310-Q0008_STD_182_20120630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_2_5">16552</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE402953--1310-Q0008_STD_182_20120630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_2_24">-729336</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE402953--1310-Q0008_STD_182_20120630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_4_3">3362400</us-gaap:ResearchAndDevelopmentExpense>
  <mnov:ProceedsOrPaymentsForIssuanceOrRepurchaseOfCommonStockNet contextRef="eol_PE402953--1310-Q0008_STD_182_20120630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_2_31">27889</mnov:ProceedsOrPaymentsForIssuanceOrRepurchaseOfCommonStockNet>
  <mnov:WarrantsExercised contextRef="eol_PE402953--1310-Q0008_STD_182_20120630_0" unitRef="shares" decimals="0" id="id_2677847_CAFC5452-4A4E-45FC-95E8-A251AC1FF285_5_1">0</mnov:WarrantsExercised>
  <mnov:IncreaseDecreaseInAccountsPayableAccruedExpensesIncomeTaxesPayableAndDeferredRent contextRef="eol_PE402953--1310-Q0008_STD_182_20120630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_2_12">-405921</mnov:IncreaseDecreaseInAccountsPayableAccruedExpensesIncomeTaxesPayableAndDeferredRent>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE402953--1310-Q0008_STD_182_20120630_0_712080x710630" unitRef="iso4217_USD" decimals="0" id="id_2677847_F2CBBBB1-EF2F-453A-B8CA-07DCF638AB21_1004_1">214000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE402953--1310-Q0008_STD_182_20120630_0_712080x713040" unitRef="iso4217_USD" decimals="0" id="id_2677847_F2CBBBB1-EF2F-453A-B8CA-07DCF638AB21_2004_2">148000</us-gaap:ShareBasedCompensation>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE402953--1310-Q0008_STD_182_20120630_0_712382x708980" unitRef="shares" decimals="INF" id="id_2677847_E9B8A637-0905-4145-A2C7-7F4ED0B1E977_1002_1">2757914</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE402953--1310-Q0008_STD_182_20120630_0_712382x710593" unitRef="shares" decimals="INF" id="id_2677847_E9B8A637-0905-4145-A2C7-7F4ED0B1E977_2002_0">2200000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE402953--1310-Q0008_STD_182_20120630_0_712382x715581" unitRef="shares" decimals="INF" id="id_2677847_E9B8A637-0905-4145-A2C7-7F4ED0B1E977_3002_2">2998686</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE402953--1310-Q0008_STD_182_20120630_0_713115x808458" unitRef="iso4217_USD" decimals="0" id="id_2677847_F2CBBBB1-EF2F-453A-B8CA-07DCF638AB21_3004_0">362000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE402953--1310-Q0008_STD_182_20120630_0_716413x708980" unitRef="pure" decimals="4" id="id_2677847_ED8E0284-3349-4777-A252-B1EAC47E6111_1004_1">0.0051</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE402953--1310-Q0008_STD_182_20120630_0_716413x708980" unitRef="pure" decimals="4" id="id_2677847_ED8E0284-3349-4777-A252-B1EAC47E6111_1004_2">0.7858</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE402953--1310-Q0008_STD_182_20120630_0_716413x708980" id="id_2677847_ED8E0284-3349-4777-A252-B1EAC47E6111_1004_4">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE402953--1310-Q0008_STD_182_20120630_0_716413x708980" unitRef="pure" decimals="3" id="id_2677847_ED8E0284-3349-4777-A252-B1EAC47E6111_1004_3">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE402953--1310-Q0008_STD_182_20120630_0_716413x715677" unitRef="pure" decimals="4" id="id_2677847_ED8E0284-3349-4777-A252-B1EAC47E6111_2004_6">0.0043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE402953--1310-Q0008_STD_182_20120630_0_716413x715677" unitRef="pure" decimals="4" id="id_2677847_ED8E0284-3349-4777-A252-B1EAC47E6111_2004_7">0.7611</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE402953--1310-Q0008_STD_182_20120630_0_716413x715677" id="id_2677847_ED8E0284-3349-4777-A252-B1EAC47E6111_2004_9">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE402953--1310-Q0008_STD_182_20120630_0_716413x715677" unitRef="pure" decimals="3" id="id_2677847_ED8E0284-3349-4777-A252-B1EAC47E6111_2004_8">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForCash contextRef="eol_PE402953--1310-Q0008_STD_22_20130509_0_709650x713713_717061x709629" unitRef="shares" decimals="0" id="id_2677847_2EE7C9C8-3377-45E5-9E83-FC975C5FB7CA_1001_0">1158730</us-gaap:StockIssuedDuringPeriodSharesIssuedForCash>
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForCash contextRef="eol_PE402953--1310-Q0008_STD_22_20130509_0_709650x713713_734171x772521" unitRef="shares" decimals="0" id="id_2677847_054A7B11-702F-4790-A78F-38E35EAE70D6_1001_0">1158730</us-gaap:StockIssuedDuringPeriodSharesIssuedForCash>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE402953--1310-Q0008_STD_22_20130509_0_709650x715581_717061x709629" unitRef="shares" decimals="INF" id="id_2677847_2EE7C9C8-3377-45E5-9E83-FC975C5FB7CA_2001_1">869047</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:EquityIssuancePerShareAmount contextRef="eol_PE402953--1310-Q0008_STD_22_20130509_0_734171x772521" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2677847_054A7B11-702F-4790-A78F-38E35EAE70D6_2001_1">3.15</us-gaap:EquityIssuancePerShareAmount>
  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="eol_PE402953--1310-Q0008_STD_22_20130509_0_734171x772521" unitRef="iso4217_USD" decimals="-5" id="id_2677847_054A7B11-702F-4790-A78F-38E35EAE70D6_2001_5">300000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="eol_PE402953--1310-Q0008_STD_22_20130509_0_734171x772521" unitRef="iso4217_USD" decimals="-5" id="id_2677847_054A7B11-702F-4790-A78F-38E35EAE70D6_2001_4">3700000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForCash contextRef="eol_PE402953--1310-Q0008_STD_29_20130529_0_709650x713713_797208x760742" unitRef="shares" decimals="0" id="id_2677847_AF7F1EB4-6432-4529-9748-45C079E09404_1001_0">158730</us-gaap:StockIssuedDuringPeriodSharesIssuedForCash>
  <mnov:ValueOfConsiderationReceived contextRef="eol_PE402953--1310-Q0008_STD_29_20130529_0_797208x760742" unitRef="iso4217_USD" decimals="0" id="id_2677847_AF7F1EB4-6432-4529-9748-45C079E09404_2001_2">51389</mnov:ValueOfConsiderationReceived>
  <us-gaap:LossContingencyDamagesSoughtValue contextRef="eol_PE402953--1310-Q0008_STD_30_20130430_0" unitRef="iso4217_USD" decimals="INF" id="id_2677847_4A277D14-8CCF-48F0-82BD-C4E671C22F2A_1_0">100000</us-gaap:LossContingencyDamagesSoughtValue>
  <us-gaap:EquityIssuancePerShareAmount contextRef="eol_PE402953--1310-Q0008_STD_30_20130430_0_705999x732135_711502x711169_734171x806301" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2677847_E4116147-5666-4500-819F-F07D0ADDBCB6_1002_3">1.19</us-gaap:EquityIssuancePerShareAmount>
  <us-gaap:SaleOfStockDescriptionOfTransaction contextRef="eol_PE402953--1310-Q0008_STD_30_20130430_0_705999x732135_734171x806301" id="id_2677847_E4116147-5666-4500-819F-F07D0ADDBCB6_3002_2">10% of the lower of the 5-day  or 3-month average daily traded value of our common stock</us-gaap:SaleOfStockDescriptionOfTransaction>
  <mnov:SalesCommission contextRef="eol_PE402953--1310-Q0008_STD_30_20130430_0_705999x732135_734171x806301" unitRef="pure" decimals="3" id="id_2677847_E4116147-5666-4500-819F-F07D0ADDBCB6_3002_4">0.080</mnov:SalesCommission>
  <mnov:CommonStockMaximumSaleAmountUnderPurchaseAgreement contextRef="eol_PE402953--1310-Q0008_STD_30_20130430_0_705999x732135_734171x806301" unitRef="iso4217_USD" decimals="0" id="id_2677847_E4116147-5666-4500-819F-F07D0ADDBCB6_3002_1">50000</mnov:CommonStockMaximumSaleAmountUnderPurchaseAgreement>
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForCash contextRef="eol_PE402953--1310-Q0008_STD_31_20111031_0_709650x713713" unitRef="shares" decimals="0" id="id_2677847_9F4EDBF1-50EB-497C-9A01-EE6166B1A9AD_1001_2">800000</us-gaap:StockIssuedDuringPeriodSharesIssuedForCash>
  <us-gaap:EquityIssuancePerShareAmount contextRef="eol_PE402953--1310-Q0008_STD_31_20111031_0_709650x713713" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2677847_9F4EDBF1-50EB-497C-9A01-EE6166B1A9AD_1001_5">2.50</us-gaap:EquityIssuancePerShareAmount>
  <us-gaap:EquityIssuancePerShareAmount contextRef="eol_PE402953--1310-Q0008_STD_31_20111031_0_711196x710990" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2677847_9F4EDBF1-50EB-497C-9A01-EE6166B1A9AD_2001_4">25.00</us-gaap:EquityIssuancePerShareAmount>
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForCash contextRef="eol_PE402953--1310-Q0008_STD_31_20111031_0_711196x710990_734171x796264" unitRef="shares" decimals="0" id="id_2677847_9F4EDBF1-50EB-497C-9A01-EE6166B1A9AD_3001_1">220000</us-gaap:StockIssuedDuringPeriodSharesIssuedForCash>
  <us-gaap:ConvertiblePreferredStockTermsOfConversion contextRef="eol_PE402953--1310-Q0008_STD_31_20111031_0_734171x796264" id="id_2677847_9F4EDBF1-50EB-497C-9A01-EE6166B1A9AD_4001_8">Each share of the  Series B Preferred is convertible into 10 shares of common stock.</us-gaap:ConvertiblePreferredStockTermsOfConversion>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForCash contextRef="eol_PE402953--1310-Q0008_STD_31_20111031_0_734171x796264" unitRef="iso4217_USD" decimals="-5" id="id_2677847_9F4EDBF1-50EB-497C-9A01-EE6166B1A9AD_4001_0">7500000</us-gaap:StockIssuedDuringPeriodValueIssuedForCash>
  <us-gaap:VariableInterestEntityOwnershipPercentage contextRef="eol_PE402953--1310-Q0008_STD_31_20120331_0" unitRef="pure" decimals="2" id="id_2677847_5838D125-076D-4BB8-B8AF-2891F45F2C87_1_2">0.70</us-gaap:VariableInterestEntityOwnershipPercentage>
  <us-gaap:PaymentsToAcquireInterestInJointVenture contextRef="eol_PE402953--1310-Q0008_STD_31_20120331_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_5838D125-076D-4BB8-B8AF-2891F45F2C87_1_0">680000</us-gaap:PaymentsToAcquireInterestInJointVenture>
  <mnov:ClassOfWarrantOrRightsExercisablePeriodFromDateOfIssuance contextRef="eol_PE402953--1310-Q0008_STD_31_20120831_0" id="id_2677847_598615ED-0C0F-4316-97A2-6F2C5CA95095_1_2">P15M</mnov:ClassOfWarrantOrRightsExercisablePeriodFromDateOfIssuance>
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForCash contextRef="eol_PE402953--1310-Q0008_STD_31_20120831_0_705999x827742_709650x713713_734171x796264" unitRef="shares" decimals="0" id="id_2677847_9CF8DC32-C639-4465-AAAF-4A3E5A13BD94_3001_3">363636</us-gaap:StockIssuedDuringPeriodSharesIssuedForCash>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForCash contextRef="eol_PE402953--1310-Q0008_STD_31_20120831_0_705999x827742_709650x713713_734171x796264" unitRef="iso4217_USD" decimals="-6" id="id_2677847_9CF8DC32-C639-4465-AAAF-4A3E5A13BD94_3001_1">1000000</us-gaap:StockIssuedDuringPeriodValueIssuedForCash>
  <mnov:StockSubscriptionAgreementMaximumNumberOfShares contextRef="eol_PE402953--1310-Q0008_STD_31_20120831_0_705999x827742_709650x713713_734171x796264" unitRef="shares" decimals="0" id="id_2677847_9CF8DC32-C639-4465-AAAF-4A3E5A13BD94_3001_2">3231096</mnov:StockSubscriptionAgreementMaximumNumberOfShares>
  <mnov:SaleDurationForCommonStockUnderPurchaseAgreement contextRef="eol_PE402953--1310-Q0008_STD_31_20120831_0_705999x827742_709650x713713_734171x796264" id="id_2677847_9CF8DC32-C639-4465-AAAF-4A3E5A13BD94_3001_4">P2Y</mnov:SaleDurationForCommonStockUnderPurchaseAgreement>
  <mnov:NumberOfConsecutiveBusinessDay contextRef="eol_PE402953--1310-Q0008_STD_31_20120831_0_705999x827742_709650x713713_734171x796264" id="id_2677847_9CF8DC32-C639-4465-AAAF-4A3E5A13BD94_3001_8">P12D</mnov:NumberOfConsecutiveBusinessDay>
  <mnov:NumberOfLowestClosingStockPrices contextRef="eol_PE402953--1310-Q0008_STD_31_20120831_0_705999x827742_709650x713713_734171x796264" unitRef="pure" decimals="0" id="id_2677847_9CF8DC32-C639-4465-AAAF-4A3E5A13BD94_3001_7">3</mnov:NumberOfLowestClosingStockPrices>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent contextRef="eol_PE402953--1310-Q0008_STD_365_20071231_0" unitRef="pure" decimals="2" id="id_2677847_BA131555-A95F-482C-8301-BA2C44423299_1_1">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
  <mnov:EmployeeStockPurchasePlanSharePurchaseOfferingPeriod contextRef="eol_PE402953--1310-Q0008_STD_365_20071231_0" id="id_2677847_BA131555-A95F-482C-8301-BA2C44423299_1_2">P6M</mnov:EmployeeStockPurchasePlanSharePurchaseOfferingPeriod>
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForCash contextRef="eol_PE402953--1310-Q0008_STD_39_20130808_0_705999x732135_710720x791689_734171x806301" unitRef="shares" decimals="0" id="id_2677847_A831F5F0-3A20-47CD-8BBF-F107A24FDC9E_2002_1">165266</us-gaap:StockIssuedDuringPeriodSharesIssuedForCash>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE402953--1310-Q0008_STD_39_20130808_0_705999x732135_710720x791689_734171x806301" unitRef="iso4217_USD" decimals="-5" id="id_2677847_A831F5F0-3A20-47CD-8BBF-F107A24FDC9E_2002_0">400000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1 contextRef="eol_PE402953--1310-Q0008_STD_4656_20130630_0" unitRef="shares" decimals="INF" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_3_39">2882258</us-gaap:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE402953--1310-Q0008_STD_4656_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_3_16">-214431373</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:DeferredRevenuePeriodIncreaseDecrease contextRef="eol_PE402953--1310-Q0008_STD_4656_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_3_4">-805837</us-gaap:DeferredRevenuePeriodIncreaseDecrease>
  <us-gaap:RepaymentsOfOtherDebt contextRef="eol_PE402953--1310-Q0008_STD_4656_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_3_33">17605485</us-gaap:RepaymentsOfOtherDebt>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE402953--1310-Q0008_STD_4656_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_3_21">2405290</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:UnrealizedGainLossOnInvestments contextRef="eol_PE402953--1310-Q0008_STD_4656_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_5_7">-1735212</us-gaap:UnrealizedGainLossOnInvestments>
  <us-gaap:RepaymentsOfDebt contextRef="eol_PE402953--1310-Q0008_STD_4656_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_3_32">15000000</us-gaap:RepaymentsOfDebt>
  <us-gaap:OtherNonoperatingIncome contextRef="eol_PE402953--1310-Q0008_STD_4656_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_5_10">19151700</us-gaap:OtherNonoperatingIncome>
  <us-gaap:IncomeTaxesPaid contextRef="eol_PE402953--1310-Q0008_STD_4656_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_3_43">72346</us-gaap:IncomeTaxesPaid>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE402953--1310-Q0008_STD_4656_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_5_16">-301438840</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="eol_PE402953--1310-Q0008_STD_4656_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_3_18">2829785</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
  <us-gaap:PaymentsToAcquireInterestInJointVenture contextRef="eol_PE402953--1310-Q0008_STD_4656_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_3_22">680000</us-gaap:PaymentsToAcquireInterestInJointVenture>
  <us-gaap:PaymentsToAcquireInvestments contextRef="eol_PE402953--1310-Q0008_STD_4656_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_3_19">377205766</us-gaap:PaymentsToAcquireInvestments>
  <us-gaap:InterestPaid contextRef="eol_PE402953--1310-Q0008_STD_4656_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_3_44">2487343</us-gaap:InterestPaid>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="eol_PE402953--1310-Q0008_STD_4656_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_5_11">-269999213</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="eol_PE402953--1310-Q0008_STD_4656_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_5_21">-78594</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
  <us-gaap:Revenues contextRef="eol_PE402953--1310-Q0008_STD_4656_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_5_0">2364064</us-gaap:Revenues>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE402953--1310-Q0008_STD_4656_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_3_11">429231</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE402953--1310-Q0008_STD_4656_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_5_22">-301517434</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE402953--1310-Q0008_STD_4656_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_5_6">-283415128</us-gaap:OperatingIncomeLoss>
  <us-gaap:IncreaseDecreaseOfRestrictedInvestments contextRef="eol_PE402953--1310-Q0008_STD_4656_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_3_14">-5982</us-gaap:IncreaseDecreaseOfRestrictedInvestments>
  <us-gaap:GainLossOnDispositionOfAssets contextRef="eol_PE402953--1310-Q0008_STD_4656_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_3_8">-6660</us-gaap:GainLossOnDispositionOfAssets>
  <us-gaap:NetIncomeLoss contextRef="eol_PE402953--1310-Q0008_STD_4656_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_5_13">-270075718</us-gaap:NetIncomeLoss>
  <us-gaap:ConversionOfStockAmountConverted1 contextRef="eol_PE402953--1310-Q0008_STD_4656_20130630_0" unitRef="iso4217_USD" decimals="INF" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_3_40">43515677</us-gaap:ConversionOfStockAmountConverted1>
  <us-gaap:OtherNonoperatingExpense contextRef="eol_PE402953--1310-Q0008_STD_4656_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_5_8">394755</us-gaap:OtherNonoperatingExpense>
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="eol_PE402953--1310-Q0008_STD_4656_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_3_13">394669</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE402953--1310-Q0008_STD_4656_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_5_4">115824039</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE402953--1310-Q0008_STD_4656_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_3_34">231389809</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE402953--1310-Q0008_STD_4656_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_3_3">50912217</us-gaap:ShareBasedCompensation>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE402953--1310-Q0008_STD_4656_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_3_35">12017480</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:OperatingExpenses contextRef="eol_PE402953--1310-Q0008_STD_4656_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_5_5">285779192</us-gaap:OperatingExpenses>
  <us-gaap:ProceedsFromOtherDebt contextRef="eol_PE402953--1310-Q0008_STD_4656_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_3_28">17605485</us-gaap:ProceedsFromOtherDebt>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE402953--1310-Q0008_STD_4656_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_5_12">76505</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE402953--1310-Q0008_STD_4656_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_3_15">2500000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:InterestExpense contextRef="eol_PE402953--1310-Q0008_STD_4656_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_5_9">3605818</us-gaap:InterestExpense>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE402953--1310-Q0008_STD_4656_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_3_26">145423902</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="eol_PE402953--1310-Q0008_STD_4656_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_3_23">261645</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
  <us-gaap:ProceedsFromIssuanceOfDebt contextRef="eol_PE402953--1310-Q0008_STD_4656_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_3_29">14670000</us-gaap:ProceedsFromIssuanceOfDebt>
  <us-gaap:CostOfRevenue contextRef="eol_PE402953--1310-Q0008_STD_4656_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_5_2">1258421</us-gaap:CostOfRevenue>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE402953--1310-Q0008_STD_4656_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_3_5">2082234</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="eol_PE402953--1310-Q0008_STD_4656_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_3_20">377918240</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE402953--1310-Q0008_STD_4656_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_3_24">-4940956</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE402953--1310-Q0008_STD_4656_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_5_3">168696732</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="eol_PE402953--1310-Q0008_STD_4656_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_3_27">85572825</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
  <us-gaap:PreferredStockAccretionOfRedemptionDiscount contextRef="eol_PE402953--1310-Q0008_STD_4656_20130630_0" unitRef="iso4217_USD" decimals="INF" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_5_14">98445</us-gaap:PreferredStockAccretionOfRedemptionDiscount>
  <mnov:DeemedDividendResultingFromConvertiblePreferredStock contextRef="eol_PE402953--1310-Q0008_STD_4656_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_5_15">31264677</mnov:DeemedDividendResultingFromConvertiblePreferredStock>
  <mnov:RestrictedAssetsCashUnrestrictedUponConversionOfConvertibleNotes contextRef="eol_PE402953--1310-Q0008_STD_4656_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_3_41">1881815</mnov:RestrictedAssetsCashUnrestrictedUponConversionOfConvertibleNotes>
  <mnov:ImpairmentChargeGainNetOnInvestmentSecuritiesAndArsPut contextRef="eol_PE402953--1310-Q0008_STD_4656_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_3_7">-1735212</mnov:ImpairmentChargeGainNetOnInvestmentSecuritiesAndArsPut>
  <mnov:ProceedsOrPaymentsForIssuanceOrRepurchaseOfCommonStockNet contextRef="eol_PE402953--1310-Q0008_STD_4656_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_3_31">-1158171</mnov:ProceedsOrPaymentsForIssuanceOrRepurchaseOfCommonStockNet>
  <mnov:ImpairmentOfSublease contextRef="eol_PE402953--1310-Q0008_STD_4656_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_3_9">35259</mnov:ImpairmentOfSublease>
  <mnov:IncreaseDecreaseInAccountsPayableAccruedExpensesIncomeTaxesPayableAndDeferredRent contextRef="eol_PE402953--1310-Q0008_STD_4656_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_3_12">306545</mnov:IncreaseDecreaseInAccountsPayableAccruedExpensesIncomeTaxesPayableAndDeferredRent>
  <mnov:AmortizationOfPremiumDiscountOnInvestmentSecuritiesConvertibleNotesAndDebtDiscountAndIssuanceCosts contextRef="eol_PE402953--1310-Q0008_STD_4656_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_3_6">1099365</mnov:AmortizationOfPremiumDiscountOnInvestmentSecuritiesConvertibleNotesAndDebtDiscountAndIssuanceCosts>
  <mnov:ProceedsFromConversionOfConvertibleNotes contextRef="eol_PE402953--1310-Q0008_STD_4656_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BE2881B3-78AD-4497-AF8E-8E6F3CE08A20_3_30">1881253</mnov:ProceedsFromConversionOfConvertibleNotes>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod contextRef="eol_PE402953--1310-Q0008_STD_91_20120630_0" unitRef="shares" decimals="INF" id="id_2677847_BA131555-A95F-482C-8301-BA2C44423299_4_3">15550</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE402953--1310-Q0008_STD_91_20120630_0" unitRef="shares" decimals="INF" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_2_18">16143125</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE402953--1310-Q0008_STD_91_20120630_0" unitRef="shares" decimals="INF" id="id_2677847_F2CBBBB1-EF2F-453A-B8CA-07DCF638AB21_2_3">60000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE402953--1310-Q0008_STD_91_20120630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_2_17">-0.14</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="eol_PE402953--1310-Q0008_STD_91_20120630_0" unitRef="shares" decimals="INF" id="id_2677847_E33F0F93-E85E-4509-8267-7BC998C714AD_3_0">15000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned contextRef="eol_PE402953--1310-Q0008_STD_91_20120630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BD5FAE21-42B4-4A69-8B8B-3F39112EEBE5_3_1">500000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
  <us-gaap:OtherNonoperatingIncome contextRef="eol_PE402953--1310-Q0008_STD_91_20120630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_2_10">6935</us-gaap:OtherNonoperatingIncome>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE402953--1310-Q0008_STD_91_20120630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_2_16">-2281350</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="eol_PE402953--1310-Q0008_STD_91_20120630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_2_11">-2281350</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="eol_PE402953--1310-Q0008_STD_91_20120630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_2_21">1905</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
  <us-gaap:Revenues contextRef="eol_PE402953--1310-Q0008_STD_91_20120630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_2_0">493623</us-gaap:Revenues>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE402953--1310-Q0008_STD_91_20120630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_2_22">-2279445</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE402953--1310-Q0008_STD_91_20120630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_2_6">-2288204</us-gaap:OperatingIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="eol_PE402953--1310-Q0008_STD_91_20120630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_2_13">-2281350</us-gaap:NetIncomeLoss>
  <us-gaap:OtherNonoperatingExpense contextRef="eol_PE402953--1310-Q0008_STD_91_20120630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_2_8">81</us-gaap:OtherNonoperatingExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE402953--1310-Q0008_STD_91_20120630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_2_4">1297888</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:OperatingExpenses contextRef="eol_PE402953--1310-Q0008_STD_91_20120630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_2_5">2781827</us-gaap:OperatingExpenses>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="eol_PE402953--1310-Q0008_STD_91_20120630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_F2CBBBB1-EF2F-453A-B8CA-07DCF638AB21_2_4">138000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE402953--1310-Q0008_STD_91_20120630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_2_3">1483939</us-gaap:ResearchAndDevelopmentExpense>
  <mnov:WarrantsExercised contextRef="eol_PE402953--1310-Q0008_STD_91_20120630_0" unitRef="shares" decimals="0" id="id_2677847_CAFC5452-4A4E-45FC-95E8-A251AC1FF285_4_1">0</mnov:WarrantsExercised>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE402953--1310-Q0008_STD_91_20120630_0_712080x710630" unitRef="iso4217_USD" decimals="0" id="id_2677847_F2CBBBB1-EF2F-453A-B8CA-07DCF638AB21_1002_1">-432000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE402953--1310-Q0008_STD_91_20120630_0_712080x713040" unitRef="iso4217_USD" decimals="0" id="id_2677847_F2CBBBB1-EF2F-453A-B8CA-07DCF638AB21_2002_2">-134000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE402953--1310-Q0008_STD_91_20120630_0_713115x808458" unitRef="iso4217_USD" decimals="0" id="id_2677847_F2CBBBB1-EF2F-453A-B8CA-07DCF638AB21_3002_0">-566000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE402953--1310-Q0008_STD_91_20120630_0_716413x708980" unitRef="pure" decimals="4" id="id_2677847_ED8E0284-3349-4777-A252-B1EAC47E6111_1002_1">0.0051</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE402953--1310-Q0008_STD_91_20120630_0_716413x708980" unitRef="pure" decimals="4" id="id_2677847_ED8E0284-3349-4777-A252-B1EAC47E6111_1002_2">0.7858</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE402953--1310-Q0008_STD_91_20120630_0_716413x708980" id="id_2677847_ED8E0284-3349-4777-A252-B1EAC47E6111_1002_4">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE402953--1310-Q0008_STD_91_20120630_0_716413x708980" unitRef="pure" decimals="3" id="id_2677847_ED8E0284-3349-4777-A252-B1EAC47E6111_1002_3">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE402953--1310-Q0008_STD_91_20120630_0_716413x715677" unitRef="pure" decimals="4" id="id_2677847_ED8E0284-3349-4777-A252-B1EAC47E6111_2002_6">0.0016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE402953--1310-Q0008_STD_91_20120630_0_716413x715677" unitRef="pure" decimals="4" id="id_2677847_ED8E0284-3349-4777-A252-B1EAC47E6111_2002_7">0.7434</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE402953--1310-Q0008_STD_91_20120630_0_716413x715677" id="id_2677847_ED8E0284-3349-4777-A252-B1EAC47E6111_2002_9">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE402953--1310-Q0008_STD_91_20120630_0_716413x715677" unitRef="pure" decimals="3" id="id_2677847_ED8E0284-3349-4777-A252-B1EAC47E6111_2002_8">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod contextRef="eol_PE402953--1310-Q0008_STD_91_20130630_0" unitRef="shares" decimals="INF" id="id_2677847_BA131555-A95F-482C-8301-BA2C44423299_2_3">16067</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE402953--1310-Q0008_STD_91_20130630_0" unitRef="shares" decimals="INF" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_1_18">20299164</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE402953--1310-Q0008_STD_91_20130630_0" unitRef="shares" decimals="INF" id="id_2677847_F2CBBBB1-EF2F-453A-B8CA-07DCF638AB21_1_3">38085</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE402953--1310-Q0008_STD_91_20130630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_1_17">-0.14</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="eol_PE402953--1310-Q0008_STD_91_20130630_0" unitRef="shares" decimals="INF" id="id_2677847_E33F0F93-E85E-4509-8267-7BC998C714AD_1_0">867500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned contextRef="eol_PE402953--1310-Q0008_STD_91_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_BD5FAE21-42B4-4A69-8B8B-3F39112EEBE5_2_1">0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
  <us-gaap:OtherNonoperatingIncome contextRef="eol_PE402953--1310-Q0008_STD_91_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_1_10">5049</us-gaap:OtherNonoperatingIncome>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE402953--1310-Q0008_STD_91_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_1_16">-2786029</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="eol_PE402953--1310-Q0008_STD_91_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_1_11">-2784240</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="eol_PE402953--1310-Q0008_STD_91_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_1_21">-3724</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE402953--1310-Q0008_STD_91_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_1_22">-2789753</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE402953--1310-Q0008_STD_91_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_1_6">-2788197</us-gaap:OperatingIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="eol_PE402953--1310-Q0008_STD_91_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_1_13">-2786029</us-gaap:NetIncomeLoss>
  <us-gaap:OtherNonoperatingExpense contextRef="eol_PE402953--1310-Q0008_STD_91_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_1_8">1092</us-gaap:OtherNonoperatingExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE402953--1310-Q0008_STD_91_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_1_4">1842092</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:OperatingExpenses contextRef="eol_PE402953--1310-Q0008_STD_91_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_1_5">2788197</us-gaap:OperatingExpenses>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE402953--1310-Q0008_STD_91_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_1_12">1789</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:ProceedsFromWarrantExercises contextRef="eol_PE402953--1310-Q0008_STD_91_20130630_0" unitRef="iso4217_USD" decimals="-5" id="id_2677847_CAFC5452-4A4E-45FC-95E8-A251AC1FF285_2_3">400000</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="eol_PE402953--1310-Q0008_STD_91_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_F2CBBBB1-EF2F-453A-B8CA-07DCF638AB21_1_4">92000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE402953--1310-Q0008_STD_91_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_2677847_2B31AE2A-C503-41E4-A305-8D41D3971944_1_3">946105</us-gaap:ResearchAndDevelopmentExpense>
  <mnov:WarrantsExercised contextRef="eol_PE402953--1310-Q0008_STD_91_20130630_0" unitRef="shares" decimals="0" id="id_2677847_CAFC5452-4A4E-45FC-95E8-A251AC1FF285_2_1">121666</mnov:WarrantsExercised>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE402953--1310-Q0008_STD_91_20130630_0_712080x710630" unitRef="iso4217_USD" decimals="0" id="id_2677847_F2CBBBB1-EF2F-453A-B8CA-07DCF638AB21_1001_1">234000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE402953--1310-Q0008_STD_91_20130630_0_712080x713040" unitRef="iso4217_USD" decimals="0" id="id_2677847_F2CBBBB1-EF2F-453A-B8CA-07DCF638AB21_2001_2">130000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE402953--1310-Q0008_STD_91_20130630_0_713115x808458" unitRef="iso4217_USD" decimals="0" id="id_2677847_F2CBBBB1-EF2F-453A-B8CA-07DCF638AB21_3001_0">364000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE402953--1310-Q0008_STD_91_20130630_0_716413x708980" unitRef="pure" decimals="4" id="id_2677847_ED8E0284-3349-4777-A252-B1EAC47E6111_1001_1">0.0080</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE402953--1310-Q0008_STD_91_20130630_0_716413x708980" unitRef="pure" decimals="4" id="id_2677847_ED8E0284-3349-4777-A252-B1EAC47E6111_1001_2">0.8610</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE402953--1310-Q0008_STD_91_20130630_0_716413x708980" id="id_2677847_ED8E0284-3349-4777-A252-B1EAC47E6111_1001_4">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE402953--1310-Q0008_STD_91_20130630_0_716413x708980" unitRef="pure" decimals="3" id="id_2677847_ED8E0284-3349-4777-A252-B1EAC47E6111_1001_3">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE402953--1310-Q0008_STD_91_20130630_0_716413x715677" unitRef="pure" decimals="4" id="id_2677847_ED8E0284-3349-4777-A252-B1EAC47E6111_2001_6">0.0015</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE402953--1310-Q0008_STD_91_20130630_0_716413x715677" unitRef="pure" decimals="4" id="id_2677847_ED8E0284-3349-4777-A252-B1EAC47E6111_2001_7">0.9160</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE402953--1310-Q0008_STD_91_20130630_0_716413x715677" id="id_2677847_ED8E0284-3349-4777-A252-B1EAC47E6111_2001_9">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE402953--1310-Q0008_STD_91_20130630_0_716413x715677" unitRef="pure" decimals="3" id="id_2677847_ED8E0284-3349-4777-A252-B1EAC47E6111_2001_8">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <context id="eol_PE402953--1310-Q0008_STD_91_20130630_0_716413x715677">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-04-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_91_20130630_0_716413x708980">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-04-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_91_20130630_0_713115x808458">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mnov:StockOptionsAndEmployeeStockPurchasePlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-04-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_91_20130630_0_712080x713040">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-04-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_91_20130630_0_712080x710630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-04-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_91_20130630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
    </entity>
    <period>
      <startDate>2013-04-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_91_20120630_0_716413x715677">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-04-01</startDate>
      <endDate>2012-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_91_20120630_0_716413x708980">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-04-01</startDate>
      <endDate>2012-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_91_20120630_0_713115x808458">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mnov:StockOptionsAndEmployeeStockPurchasePlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-04-01</startDate>
      <endDate>2012-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_91_20120630_0_712080x713040">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-04-01</startDate>
      <endDate>2012-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_91_20120630_0_712080x710630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-04-01</startDate>
      <endDate>2012-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_91_20120630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
    </entity>
    <period>
      <startDate>2012-04-01</startDate>
      <endDate>2012-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_4656_20130630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
    </entity>
    <period>
      <startDate>2000-10-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_39_20130808_0_705999x732135_710720x791689_734171x806301">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnov:MacquarieCapitalIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="mnov:SharePurchaseAgreementAxis">mnov:AtMarketSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">mnov:EquityDistributionAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-08-08</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_365_20071231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
    </entity>
    <period>
      <startDate>2007-01-01</startDate>
      <endDate>2007-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_31_20120831_0_705999x827742_709650x713713_734171x796264">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnov:AspireCapitalFundLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="mnov:SharePurchaseAgreementAxis">mnov:SharePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-08-01</startDate>
      <endDate>2012-08-31</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_31_20120831_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
    </entity>
    <period>
      <startDate>2012-08-01</startDate>
      <endDate>2012-08-31</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_31_20120331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
    </entity>
    <period>
      <startDate>2012-03-01</startDate>
      <endDate>2012-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_31_20111031_0_734171x796264">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="mnov:SharePurchaseAgreementAxis">mnov:SharePurchaseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-10-01</startDate>
      <endDate>2011-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_31_20111031_0_711196x710990_734171x796264">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="mnov:SharePurchaseAgreementAxis">mnov:SharePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-10-01</startDate>
      <endDate>2011-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_31_20111031_0_711196x710990">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-10-01</startDate>
      <endDate>2011-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_31_20111031_0_709650x713713">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-10-01</startDate>
      <endDate>2011-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_30_20130430_0_705999x732135_734171x806301">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnov:MacquarieCapitalIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="mnov:SharePurchaseAgreementAxis">mnov:AtMarketSalesAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-04-01</startDate>
      <endDate>2013-04-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_30_20130430_0_705999x732135_711502x711169_734171x806301">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnov:MacquarieCapitalIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="mnov:SharePurchaseAgreementAxis">mnov:AtMarketSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-04-01</startDate>
      <endDate>2013-04-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_30_20130430_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
    </entity>
    <period>
      <startDate>2013-04-01</startDate>
      <endDate>2013-04-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_29_20130529_0_797208x760742">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="mnov:InvestorsNameAxis">mnov:InvestorOneMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-05-01</startDate>
      <endDate>2013-05-29</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_29_20130529_0_709650x713713_797208x760742">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="mnov:InvestorsNameAxis">mnov:InvestorOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-05-01</startDate>
      <endDate>2013-05-29</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_22_20130509_0_734171x772521">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="mnov:SharePurchaseAgreementAxis">mnov:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-04-18</startDate>
      <endDate>2013-05-09</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_22_20130509_0_709650x715581_717061x709629">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-04-18</startDate>
      <endDate>2013-05-09</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_22_20130509_0_709650x713713_734171x772521">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="mnov:SharePurchaseAgreementAxis">mnov:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-04-18</startDate>
      <endDate>2013-05-09</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_22_20130509_0_709650x713713_717061x709629">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-04-18</startDate>
      <endDate>2013-05-09</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_182_20120630_0_716413x715677">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_182_20120630_0_716413x708980">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_182_20120630_0_713115x808458">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mnov:StockOptionsAndEmployeeStockPurchasePlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_182_20120630_0_712382x715581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_182_20120630_0_712382x710593">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_182_20120630_0_712382x708980">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_182_20120630_0_712080x713040">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_182_20120630_0_712080x710630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_182_20120630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_181_20130630_0_716413x715677">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_181_20130630_0_716413x708980">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_181_20130630_0_713115x808458">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mnov:StockOptionsAndEmployeeStockPurchasePlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_181_20130630_0_712382x715581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_181_20130630_0_712382x710593">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_181_20130630_0_712382x708980">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_181_20130630_0_712080x713040">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_181_20130630_0_712080x710630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_181_20130630_0_705999x827742_709650x713713_734171x796264">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnov:AspireCapitalFundLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="mnov:SharePurchaseAgreementAxis">mnov:SharePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_181_20130630_0_705999x827742_709650x713713_711502x716112_734171x796264">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnov:AspireCapitalFundLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="mnov:SharePurchaseAgreementAxis">mnov:SharePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_181_20130630_0_705999x827742_709650x713713_711502x711169_734171x796264">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnov:AspireCapitalFundLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="mnov:SharePurchaseAgreementAxis">mnov:SharePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_181_20130630_0_705999x732135_734171x806301">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnov:MacquarieCapitalIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="mnov:SharePurchaseAgreementAxis">mnov:AtMarketSalesAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_181_20130630_0_705999x732135_711502x716112_734171x806301">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnov:MacquarieCapitalIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="mnov:SharePurchaseAgreementAxis">mnov:AtMarketSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_181_20130630_0_705999x732135_711502x711169_734171x806301">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnov:MacquarieCapitalIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="mnov:SharePurchaseAgreementAxis">mnov:AtMarketSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_181_20130630_0_705999x732135">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnov:MacquarieCapitalIncorporatedMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_181_20130630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_0_20121231_0_712546x711349_715757x707740">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_0_20121231_0_712546x711349">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_0_20121231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_0_20111231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_0_20071231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
    </entity>
    <period>
      <instant>2007-12-31</instant>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_0_20130630_0_712546x711349_715757x707740">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-06-30</instant>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_0_20130630_0_712546x711349">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-06-30</instant>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_0_20130630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
    </entity>
    <period>
      <instant>2013-06-30</instant>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_0_20120831_0_705999x827742_709650x713713_734171x796264">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnov:AspireCapitalFundLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="mnov:SharePurchaseAgreementAxis">mnov:SharePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-08-31</instant>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_0_20120831_0_705999x827742_709650x713713_711502x716112_734171x796264">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnov:AspireCapitalFundLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="mnov:SharePurchaseAgreementAxis">mnov:SharePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-08-31</instant>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_0_20120831_0_705999x827742_709650x713713_711502x716112">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnov:AspireCapitalFundLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-08-31</instant>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_0_20120831_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
    </entity>
    <period>
      <instant>2012-08-31</instant>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_0_20120630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
    </entity>
    <period>
      <instant>2012-06-30</instant>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_0_20130529_0_797208x760742">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="mnov:InvestorsNameAxis">mnov:InvestorOneMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-05-29</instant>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_0_20130417_0_705999x732135_734171x806301">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnov:MacquarieCapitalIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="mnov:SharePurchaseAgreementAxis">mnov:AtMarketSalesAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-04-17</instant>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_0_20120331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
    </entity>
    <period>
      <instant>2012-03-31</instant>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_0_20110323_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
    </entity>
    <period>
      <instant>2011-03-23</instant>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_0_20130807_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
    </entity>
    <period>
      <instant>2013-08-07</instant>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_0_20130509_0_734171x772521">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="mnov:SharePurchaseAgreementAxis">mnov:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-05-09</instant>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_0_20120822_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
    </entity>
    <period>
      <instant>2012-08-22</instant>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_0_20111031_0_734171x796264">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
      <segment><xbrldi:explicitMember dimension="mnov:SharePurchaseAgreementAxis">mnov:SharePurchaseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-10-31</instant>
    </period>
  </context>
  <context id="eol_PE402953--1310-Q0008_STD_0_20111031_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001226616</identifier>
    </entity>
    <period>
      <instant>2011-10-31</instant>
    </period>
  </context>
  <unit id="iso4217_USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="iso4217_USD_per_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="pure">
    <measure>pure</measure>
  </unit>
  <unit id="shares">
    <measure>shares</measure>
  </unit>
  <unit id="iso4217_USD_per_Warrants">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>mnov:Warrants</measure>
      </unitDenominator>
    </divide>
  </unit>
</xbrl>